WEST Search History

09/869,692

DATE: Saturday, May 24, 2003

Set Name side by side	Query	Hit Count	Set Name result set
	DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ		
L26	flavanolic oligomer	0	L26
L25	L24 not l6	8	L25
L24	procyanidol oligomer	8	L24
	DB=USPT; PLUR=YES; OP=ADJ		
L23	L22 not l4	13	L23
L22	procyanidol oligomer) same as procyanidolic oligomer (diff. names)	16	L22
L21	flavanolic oligomer)	3	L21
	DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ		
L20	flavanolic oligomer	0	L20
L19	l17 and (cosmetic or topical)	6	L19
L18	L17 and (l6 or polyphenol or tannin or grape or grapeseed or green tea)	1	L18
L17	((hsp or heat shock protein) near2 32) or hsp32 or heme oxygenase or ho-1	51	L17
	DB=PGPB; PLUR=YES; OP=ADJ		
L16	L15 and (l5 or polyphenol or tannin or grape or grapeseed or green tea)	4	L16
L15	((hsp or heat shock protein) near2 32) or hsp32 or heme oxygenase or ho-1	90	L15
	DB=USPT; PLUR=YES; OP=ADJ		
L14	L12 and (polyphenol or tannin or grape or grapeseed or green tea)	5	L14
L13	L12 and l4	0	L13
L12	heme oxygenase or ho-1 — same as HSP 32	134	L12
L11	L10 not l7 not l8 not l9	8	L11
L10	((hsp or heat shock protein) near3 32)	12	L10
L9	L8 not l7	4	L9
L8	hsp32	5	L8
L7	((hsp or heat shock protein) adj2 32)	3	L7
	DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ		
L6	procyanidolic oligomer	17	L6
	DB=PGPB; PLUR=YES; OP=ADJ		
L5	procyanidolic oligomer	5	L5
	DB=USPT; PLUR=YES; OP=ADJ		
L4	procyanidolic oligomer	10	L4
L3	L1 and (hsp or heat shock protein)	4	L3
L2	L1 and ((hsp or heat shock protein) adj2 32)	0	L2
L1	pco or pcos or procyanidolic oligomer	787	L1

WEST

Generate Collection | Print

L6: Entry 14 of 17 File: DWPI Jan 7, 1999

DERWENT-ACC-NO: 1999-142424
DERWENT-WEEK: 199912

TITLE: Use of crosslinked tannins and proteins that are not crosslinked with tannins, in cosmetics and - as astringents and to make skin smooth

INVENTOR: ANDRE, P; RENIMEL, I

PATENT-ASSIGNEE: PARFUMS DIOR SA CHRISTIAN (DIOR)

PRIORITY-DATA: 1997FR-0008100 (June 27, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9900110 A1	January 7, 1999	F	022	A61K007/48
FR 2765106 A1	December 31, 1998		000	A61K007/48

DESIGNATED-STATES: CA JP KR US AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
WO 9900110A1	June 26, 1998	1998WO-FR01364	
FR 2765106A1	June 27, 1997	1997FR-0008100	

not published in English

INT-CL (IPC): A61 K 7/00; A61 K 7/48

ABSTRACTED-PUB-NO: WO 9900110A
BASIC-ABSTRACT:

The use of crosslinked tannins (I) with proteins (II) that are not crosslinked with the tannins, as cosmetic agents to smooth skin and/or as astringents, is new. Also claimed is production of a stable composition containing tannins in the presence of a protein comprising crosslinking the tannins, preferably procyanidolic oligomers, prior to mixing with the protein.

The tannins are water soluble phenolic oligomers, having a molecular weight of 500-3000 Daltons, such as pure procyanidolic oligomers or natural extracts, such as from oak or grape seeds. (II) may be of animal, human or plant origin, preferably it is serum albumin, ovalbumin, alpha -lactalbumin, globulins, fibrinogen, casein, collagen, atelocollagen, gelatine and its hydrolysates, peptones, haemoglobin, soya proteins, degraded or non-degraded glytelins, solubilised scleroproteins, milk proteins and soya flour.

USE - The composition is used to make the skin firmer (claimed).

ABSTRACTED-PUB-NO: WO 9900110A
EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.1/2

DERWENT-CLASS: B04 D21
CPI-CODES: B04-A10; B04-B04D2; B04-H19; B04-N01; B04-N02; B06-A01; B07-A02B; B14-R01;

09/869,692

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1616mxl

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN
NEWS 40	May 19	Simultaneous left and right truncation added to WSCA
NEWS 41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation

```
 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:00:52 ON 24 MAY 2003

=> file medicine, kosmet
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'ADISCTI' ENTERED AT 19:01:10 ON 24 MAY 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 19:01:10 ON 24 MAY 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 19:01:10 ON 24 MAY 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 19:01:10 ON 24 MAY 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 19:01:10 ON 24 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'CAPLUS' ENTERED AT 19:01:10 ON 24 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEN' ENTERED AT 19:01:10 ON 24 MAY 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 19:01:10 ON 24 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 19:01:10 ON 24 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGLAUNCH' ENTERED AT 19:01:10 ON 24 MAY 2003
```

FILE 'DRUGMONOG2' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'DRUGNL' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'DRUGU' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'EMBAL' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'EMBASE' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'ESBIOBASE' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'IFIPAT' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'IPA' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'JICST-EPLUS' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'KOSMET' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'LIFESCI' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'MEDICONF' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'MEDLINE' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'NAPRALERT' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'NLDB' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'NUTRACEUT' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'PASCAL' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'PCTGEN' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'PHARMAML' ENTERED AT 19:01:10 ON 24 MAY 2003

FILE 'PHIC' ENTERED AT 19:01:10 ON 24 MAY 2003

COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 19:01:10 ON 24 MAY 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'SCISEARCH' ENTERED AT 19:01:10 ON 24 MAY 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'TOXCENTER' ENTERED AT 19:01:10 ON 24 MAY 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 19:01:10 ON 24 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 19:01:10 ON 24 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (procyanidol? or flavanol?) (N) oligomer
L1 102 (PROCYANIDOL? OR FLAVANOL?) (N) OLIGOMER

=> s ((hsp or heat shock protein) (n) 32) or hsp32 or heme oxygenase or ho-1
9 FILES SEARCHED...
18 FILES SEARCHED...
34 FILES SEARCHED...
L2 24806 ((HSP OR HEAT SHOCK PROTEIN) (N) 32) OR HSP32 OR HEME OXYGENASE OR HO-1

=> s l1 and l2
L3 1 L1 AND L2

=> d l3

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AN 2000:475516 CAPLUS
DN 133:94311
TI Cosmetic or dermatological composition containing an active principle stimulating **HSP 32** protein synthesis in the skin
IN Nizard, Carine; Moreau, Marielle; Bonte, Frederic
PA Parfums Christian Dior, Fr.
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000040215	A1	20000713	WO 1999-FR3310	19991229
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FR 2787996	A1	20000707	FR 1998-16641	19981230
	FR 2787996	B1	20020510		
	EP 1140000	A1	20011010	EP 1999-964734	19991229
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	FR 1998-16641	A	19981230		
	WO 1999-FR3310	W	19991229		

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l2 and (cosmetic or topical or dermatological)
L4 157 L2 AND (COSMETIC OR TOPICAL OR DERMATOLOGICAL)

```
=> dup rem l4
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGLAUNCH,
DRUGMONOG2, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHARMAML'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L4
L5          117 DUP REM L4 (40 DUPLICATES REMOVED)

=> d l5

L5   ANSWER 1 OF 117  IFIPAT  COPYRIGHT 2003 IFI       DUPLICATE 1
AN    10347629  IFIPAT;IFIUDB;IFICDB
TI    MELANOMA DIFFERENTIATION ASSOCIATED GENE-5 AND PROMOTER AND USES THEREOF
IN    Fisher Paul B; Gopalkrishnan Rahul V; Kang Dong-Chul
PA    Unassigned Or Assigned To Individual (68000)
PI    US 2003092043   A1  20030515
AI    US 2002-228897      20020826
RLI   US 2000-515363      20000229 CONTINUATION          PENDING
FI    US 2003092043       20030515
DT    Utility; Patent Application - First Publication
FS    CHEMICAL
      APPLICATION
CLMN  35
GI     15 Figure(s).
     FIGS. 1A-1D. Sequence of mda-5 and alignment with CARD and RNA helicases.
      FIG. 1A. Nucleotide sequence (SEQ ID NO:1) and corresponding amino acid
      sequence (SEQ ID NO:2) of mda-5. Underlined sequences are AUUUA
      sequences. Bold face sequence is the poly A signal. FIG. 1B. Additional
      nucleotide sequence of mda-5p (SEQ ID NO: 4). Poly A signal is bold
      faced. FIG. 1C. Alignment of CARD proteins with 50 amino acids near the
      Nterminal region of MDA-5 (a.a. 125-174 correspond to 1-50). (SEQ ID NOS:
      5-11) FIG. 1D. Alignment of the RNA helicase conserved motif of mda-5
      with eIF-4A (SEQ ID NO: 12) and p68 RNA helicases-2E (SEQ ID NO: 13).
     FIGS. 2A-2B. Northern blot analysis of mda-5 expression by various
      compounds inducing differentiation in HO-1 human
      melanoma cells. RNA samples were extracted from cells treated as
      indicated for 24 hr. FIG. 2A. HO-1 human melanoma
      cells. FIG.  2B. Early passage human skin fibroblast cells. Northern
      hybridization was performed as in Materials and Methods. Abbreviations
      and concentration of the indicated reagents are as follows: ctl, control;
      DMSO, 0.1% dimethyl sulfoxide; EtOH, 0.25% final concentration of
      ethanol; Mez, mezerein 10 ng/ml; IFN-beta, 2,000 U/ml interferon-beta ;
      IFN-beta +Mez, 2,000 U/ml interferon-beta plus mezerein 10 ng/ml;
      IFN-gamma, interferon-gamma 100 U/ml; IFN-gamma +Mez, interferon-gamma
      100 U/ml plus mezerein 10 ng/ml; RA, all-trans-retinoic acid 2. 5 B5M
      (dissolved in EtOH): MPA, mycophenolic acid 3 BSM; TPA,12O-
      tetradecanoylphorbol-13-acetate 16 nM; cAMP, 3'-5' cyclic adenosine
      monophosphate 1 mM; 8-Br-cAMP, 8-bromo-3'-5' cyclic adenosine
      monophosphate 1 mM; MMS, methylmethane sulfonate 10 ng/ml; poly IC 10 mu
      g/ml.
     FIG. 3. Northern blot analysis of mda-5 expression induced by IFN-beta in
      normal and tumor cell lines. RNA samples were extracted from the
      indicated cells treated with 2,000 U/ml of interferon-beta for 24 hr.
      Northern hybridization was performed as in Materials and Methods.
     FIGS. 4A-4B. Northern blot analysis of mda-5 expression by ligands for
      various membrane receptors. RNA samples were extracted from cells treated
      as indicated for 24 hr. FIG. 4A. HO-1 human melanoma
      cells. FIG. 4B. Early passage human skin fibroblast cells. Northern
      hybridization was performed as in Materials and Methods. Abbreviations
      and concentrations of indicated reagents are as follows: ctl, control;
      IFN-alpha, 1, 000 U/ml interferon-alpha IFN-beta, 1,000 U/ml
      interferonbeta IFN-gamma, 1,000 U/ml interferon-gamma, IL-6,
      interleukin-6, 1 ng/ml; EGF, epidermal growth factor, 10 ng/ml;
      TGF-alpha, transforming growth factor alpha, 10 ng/ml; TGFbeta
      transforming growth factor beta, 2.5 ng/ml; TNF-alpha, tumor necrosis
```

factor alpha, 10 ng/ml; PDGF, platelet-derived growth factor, 10 ng/ml.

FIG. 5. Northern blot analysis and time course of mda-5 expression. RNA samples were extracted from **HO-1** cells treated with the indicated reagents and harvested at the indicated time after treatment. Northern blotting was performed as in Materials and Methods. Abbreviations and concentrations of the indicated reagents are as follows: Mez, mezerein 10 ng/ml; IFNbeta, 2,000 U/ml interferon-beta ; IFN-beta +Mez, 2,000 U/ml interferon-beta plus mezerein 10 ng/ml.

FIG. 6. Northern blot analysis of mda-5 expression in different organs. Multiple tissue Northern blots were purchased from ClonTech. Each lane contains 2 mu g of poly A+ RZNA. Northern hybridization was performed as described in Materials and Methods.

FIGS. 7A-7C. Mechanism of induction of mda-5 expression. A. Northern blot analysis of mda-5. **HO-1** melanoma cells were treated with 5 mu g/ml actinomycin D 24 hr after incubation with 2,000 U/ml IFN-beta or 2,000 U/ml IFN-beta +10 ng/ml Mez. Cells were harvested at the indicated time after actinomycin D treatment. Northern hybridization was performed as in Materials and Methods. FIG. 7B. Nuclear run-on assays for determining mda5 transcription rates. Nuclei were prepared from **HO-1** melanoma cells treated with the indicated reagent(s) for 4 hr. Blots were prepared and hybridized as described in Materials and Methods. Abbreviations and concentrations of the indicated reagents are as follows: mda-5 5' and 3' fragment of mda-5 cDNA, respectively; ctl, control; Mez, mezerein 10 ng/ml; IFN-beta, 2,000 U/ml interferon-beta ; IFN-beta +Mez, 2,000 U/ml interferon-beta plus mezerein 10 ng/ml. FIG. 7C. Northern blot analysis of mda-5 expression after blocking protein synthesis by cycloheximide (CHX). RNA samples were extracted from **HO-1** melanoma cells pretreated with 50 mu g/ml cycloheximide for 30 min and treated with the indicated reagents for 8 hr. Abbreviations and concentrations of indicated reagents are as in FIG. 4.

FIGS. 8A-8C. Protein expression of mda-5. FIG. 8A. Autoradiogram of 9% SDS-PAGE of in vitro translated mda-5 cDNA. Pgalactosidase was used as a positive control. FIG. 8B. Western blot analysis of mda-5 fusion protein resolved in 9% SDS-PAGE. Protein extracts were prepared from 293T cells transiently transfected with the indicated expression vector. Details of transfection and immunoblot can be found in Materials and Methods. FIG. 8C. Intracellular localization of mda-5 protein. Transiently transfected 293T cells with the indicated fusion protein constructs were mounted and observed by fluorescent confocal microscopy (400 x).

FIG. 9. The effect of ectopic expression of mda-5 on G418resistant colony formation of **HO-1** melanoma cells. **HO-1** melanoma cells were transfected and selected with G418 as in Materials and Methods. Giemsa-stained colonies containing more than about 50 cells were counted. The results are mean +standard error from three independent trnasfections (three plates for each transfection) with two different plasmid batches.

FIG. 10: The sequence of the proximal promoter region of the mda5 gene showing landmark restriction sites. The initiator Methionine codon is highlighted by an open box as is the BstXI sites used to perform an internal deletion that removed the ATG as described in the text.

FIG. 11: Screening of stable human **HO-1** melanoma clones for promoter activity of stably integrated mda-5 reporter construct. Transfected **HO-1** cells were selected by Puromycin drug selection and individual colonies analyzed for induction of luciferase activity in the presence of IFN-beta . Values are expressed as fold change against uninduced values of luciferase activity.

FIG. 12: Induction kinetics of mda-5 promoter activity. Stable clones #20 and #40 were treated with IFN-beta and samples were harvested and analyzed for luciferase activity at the times indicated.

FIG. 13: Responsiveness of the mda-5 promoter to IFN-beta levels: Stable clones #20 and #40 were treated with IFN-beta and samples were harvested and analyzed for luciferase activity 48h after initiation of treatment. The extent of activity was normalized based on equivalent protein content

and performed in duplicate for each clone.
FIGS. 14A-14B: Responsiveness of the mda-5 promoter to various inducers: FIG. 14A. **HO-1** cells transiently transfected with the mda-5 reporter and treated for 48 h with equivalent units of IFNs alpha, beta and gamma and TNF-alpha and poly IC:IC. The luciferase activity was expressed as fold increase over untreated control cells. FIG. 14B. Clone #40 was treated with equivalent units of the indicated IFNs for 48 h and luciferase activity expressed as fold activation over untreated cells determined.
FIG. 15: Induction kinetics of mda-5 promoter activity by double stranded RNA. Stable clones #20 and #40 were treated with 2 mu g/ml poly IC:IC and samples harvested and analyzed for luciferase activity at the times indicated.

```
=> s (((hsp or heat shock protein) (n) 32) or hsp32 or heme oxygenase or ho-1) (N)
(composition or application or cosmetic or topical or dermatological)
   9 FILES SEARCHED...
  18 FILES SEARCHED...
  28 FILES SEARCHED...
  35 FILES SEARCHED...
L6          126 (((HSP OR HEAT SHOCK PROTEIN) (N) 32) OR HSP32 OR HEME OXYGENASE
                OR HO-1) (N) (COMPOSITION OR APPLICATION OR COSMETIC OR TOPICAL
                OR DERMATOLOGICAL)

=> dup rem l6
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGLAUNCH,
DRUGMONOG2, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHARMAML'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L6
L7           125 DUP REM L6 (1 DUPLICATE REMOVED)

=> s l7 and (cosmetic or topical or dermatological)
  29 FILES SEARCHED...
L8            2 L7 AND (COSMETIC OR TOPICAL OR DERMATOLOGICAL)

=> d l8 kwic 1-2

L8   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS
TI   Cosmetic or dermatological composition containing an
     active principle stimulating HSP 32 protein synthesis in the skin
AB   . . . peptide fragment of such a protein. PCO stimulated the synthesis
     of HSP 32 in presence of UV by 204%. A cosmetic compn.
     contained PCO from raisin seed 0.5, ceramide-3 0.12, glycerin 2, octyl
     methoxycinnamate 7.5, Parsol-1789 2, tocopherol acetate 0.2, excipients.
     . .
ST   heat shock protein stimulant cosmetic; procyanidolic oligomer
     cosmetic methoxycinnamate UV
IT   Heat-shock proteins
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); BUU (Biological use, unclassified); BIOL (Biological
     study); USES (Uses)
        (HSP 32; cosmetic or dermatol. compn.
        contg. active principle stimulating HSP 32 protein synthesis in skin)
IT   Cosmetics
        (antiaging; cosmetic or dermatol. compn. contg. active
        principle stimulating HSP 32 protein synthesis in skin)
IT   Margosa (Melia azadirachta)
     Sunscreens
     Radical scavengers
     RL: BIOL (Biological study)
        (cosmetic or dermatol. compn. contg. active principle
        stimulating HSP 32 protein synthesis in skin)
IT   Saponins
```

Tocopherols
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** or dermatol. compn. contg. active principle stimulating HSP 32 protein synthesis in skin)

IT Cosmetics
(creams, wrinkle-preventing; **cosmetic** or dermatol. compn. contg. active principle stimulating HSP 32 protein synthesis in skin)

IT Ketones, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(diketones, unsatd., curcuminoids; **cosmetic** or dermatol. compn. contg. active principle stimulating HSP 32 protein synthesis in skin)

IT Centella asiatica
Loquat (Eriobotrya japonica)
(ext., **cosmetic** or dermatol. compn. contg. active principle stimulating HSP 32 protein synthesis in skin)

IT Coleus barbatus
Potentilla recta
(ext.; **cosmetic** or dermatol. compn. contg. active principle stimulating HSP 32 protein synthesis in skin)

IT Flavones
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(isoflavones; **cosmetic** or dermatol. compn. contg. active principle stimulating HSP 32 protein synthesis in skin)

IT Oligomers
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(procyanidolic; **cosmetic** or dermatol. compn. contg. active principle stimulating HSP 32 protein synthesis in skin)

IT 50-81-7, Vitamin c, biological studies 59-92-7, biological studies 60-18-4D, Tyrosine, malyl(sic) deriv. 331-39-5D, Caffeic acid, esters 446-72-0, Genistein 458-37-7, Curcumine 471-53-4, 18.beta.-Glycyrrhetinic acid 476-66-4, Ellagic acid 485-72-3, Formononetin 486-66-8, Daidzein 10043-83-1, Magnesium phosphate 61276-16-2, Oraposide 71276-50-1 115346-09-3, Forskolin E 216210-47-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** or dermatol. compn. contg. active principle stimulating HSP 32 protein synthesis in skin)

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
IT Drug delivery systems
(**topical**; **heme oxygenase** inhibitors, alone or in combination with other agents or with radiation, to treat cancer)

=> d l8 ibib 1-2

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:475516 CAPLUS
DOCUMENT NUMBER: 133:94311
TITLE: **Cosmetic** or **dermatological** composition containing an active principle stimulating HSP 32 protein synthesis in the skin
INVENTOR(S): Nizard, Carine; Moreau, Marielle; Bonte, Frederic

PATENT ASSIGNEE(S): Parfums Christian Dior, Fr.
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040215	A1	20000713	WO 1999-FR3310	19991229
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2787996	A1	20000707	FR 1998-16641	19981230
FR 2787996	B1	20020510		
EP 1140000	A1	20011010	EP 1999-964734	19991229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: FR 1998-16641 A 19981230
WO 1999-FR3310 W 19991229
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:650257 CAPLUS
DOCUMENT NUMBER: 127:314815
TITLE: Use of heme oxygenase inhibitors to treat cancer
INVENTOR(S): Moore, Adrian Richard; Willis, Dean; Willoughby, Derek Albert
PATENT ASSIGNEE(S): William Harvey Research Limited, UK; Moore, Adrian Richard; Willis, Dean; Willoughby, Derek Albert
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9735569	A1	19971002	WO 1997-GB844	19970326
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9721689	A1	19971017	AU 1997-21689	19970326

PRIORITY APPLN. INFO.: GB 1996-6293 19960326
WO 1997-GB844 19970326

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	110.68	110.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.65	-0.65

FILE 'STNGUIDE' ENTERED AT 19:12:11 ON 24 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 23, 2003 (20030523/UP).

=> d l6 ibib kwic 1
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, USPATFULL' - CONTINUE? (Y)/N:y

L6 ANSWER 1 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:475516 CAPLUS
DOCUMENT NUMBER: 133:94311
TITLE: Cosmetic or dermatological composition containing an active principle stimulating HSP 32 protein synthesis in the skin
INVENTOR(S): Nizard, Carine; Moreau, Marielle; Bonte, Frederic
PATENT ASSIGNEE(S): Parfums Christian Dior, Fr.
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040215	A1	20000713	WO 1999-FR3310	19991229
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2787996	A1	20000707	FR 1998-16641	19981230
FR 2787996	B1	20020510		
EP 1140000	A1	20011010	EP 1999-964734	19991229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: FR 1998-16641 A 19981230
WO 1999-FR3310 W 19991229
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT Heat-shock proteins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**HSP 32**; **cosmetic** or dermatol. compn.
contg. active principle stimulating HSP 32 protein synthesis in skin)

=> d l6 ibib kwic 2
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, USPATFULL' - CONTINUE? (Y)/N:y

L6 ANSWER 2 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:650257 CAPLUS
DOCUMENT NUMBER: 127:314815
TITLE: Use of heme oxygenase inhibitors to treat cancer
INVENTOR(S): Moore, Adrian Richard; Willis, Dean; Willoughby, Derek Albert
PATENT ASSIGNEE(S): William Harvey Research Limited, UK; Moore, Adrian Richard; Willis, Dean; Willoughby, Derek Albert

SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9735569	A1	19971002	WO 1997-GB844	19970326

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9721689	A1	19971017	AU 1997-21689	19970326

PRIORITY APPLN. INFO.: GB 1996-6293 19960326
WO 1997-GB844 19970326

IT Drug delivery systems
(**topical**; **heme oxygenase** inhibitors, alone or in combination with other agents or with radiation, to treat cancer)

=> d l6 ibib kwic 3
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, USPATFULL' - CONTINUE? (Y)/N:y

L6 ANSWER 3 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:184954 CAPLUS
DOCUMENT NUMBER: 120:184954
TITLE: Heme oxygenase induction. A possible factor in aluminum-associated anemia
AUTHOR(S): Fulton, Barbara; Jeffery, Elizabeth H.
CORPORATE SOURCE: Inst. Environ. Stud., Univ. Illinois, Urbana, IL, 61801, USA
SOURCE: Biological Trace Element Research (1994), 40(1), 9-19
CODEN: BTERDG; ISSN: 0163-4984
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Liver, **composition**
(**heme oxygenase** of, aluminum-induced anemia in relation to)

=> d l6 ibib kwic 4-10
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, USPATFULL' - CONTINUE? (Y)/N:y

L6 ANSWER 4 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:576523 CAPLUS
DOCUMENT NUMBER: 119:176523
TITLE: Rat liver heme oxygenase. High level expression of a truncated soluble form and nature of the meso-hydroxylating species
AUTHOR(S): Wilks, Angela; Ortiz de Montellano, Paul R.
CORPORATE SOURCE: Sch. Pharm., Univ. California, San Francisco, CA, 94143-0446, USA
SOURCE: Journal of Biological Chemistry (1993), 268(30),

22357-62
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Liver, **composition**
(**heme oxygenase** recombinant truncated sol. form of, of rat, expression in Escherichia coli and reaction mechanism of)

L6 ANSWER 5 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:554938 CAPLUS
DOCUMENT NUMBER: 119:154938
TITLE: Cobalt-mesoporphyrin inhibits heme oxygenase activity but it does not induce lipid peroxidation in rat brain membranes during photoirradiation
AUTHOR(S): Keino, H.; Banno, T.; Mimura, S.; Kashiwamata, S.
CORPORATE SOURCE: Dep. Perinatol., Inst. Dev. Res., Aichi, 480-03, Japan
SOURCE: Biology of the Neonate (1993), 63(5), 285-9
CODEN: BNEOBV; ISSN: 0006-3126
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Spleen, **composition**
(**heme oxygenase** of, cobalt mesoporphyrin and visible light inhibition of)

L6 ANSWER 6 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:531484 CAPLUS
DOCUMENT NUMBER: 119:131484
TITLE: Targeting zinc protoporphyrin liposomes to the spleen using reticuloendothelial blockade with blank liposomes
AUTHOR(S): Hamori, Charles J.; Lasic, Danilo D.; Vreman, Hendrik J.; Stevenson, David K.
CORPORATE SOURCE: Sch. Med., Univ. California, San Diego, CA, 92037, USA
SOURCE: Pediatric Research (1993), 34(1), 1-5
CODEN: PEREBL; ISSN: 0031-3998
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Spleen, **composition**
(**heme oxygenase** of, zinc protoporphyrin-contg. liposomes inhibition of, after reticuloendothelial blockade with blank liposomes)

L6 ANSWER 7 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:210170 CAPLUS
DOCUMENT NUMBER: 118:210170
TITLE: Glutathione depletion induces heme oxygenase-1 (HSP32) mRNA and protein in rat brain
AUTHOR(S): Ewing, James F.; Maines, Mahin D.
CORPORATE SOURCE: Sch. Med., Univ. Rochester, Rochester, NY, USA
SOURCE: Journal of Neurochemistry (1993), 60(4), 1512-19
CODEN: JONRA9; ISSN: 0022-3042
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Brain, **composition**
(**heme oxygenase**-1 of cells of, induction of, by GSH depletion)

L6 ANSWER 8 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:208325 CAPLUS
DOCUMENT NUMBER: 118:208325
TITLE: Human heme oxygenase-2: characterization and expression of a full-length cDNA and evidence suggesting that the two HO-2 transcripts may differ by choice of polyadenylation signal

AUTHOR(S): McCoubrey, William K., Jr.; Ewing, James F.; Maines, Mahin D.
CORPORATE SOURCE: Sch. Med., Univ. Rochester, Rochester, NY, 14642, USA
SOURCE: Archives of Biochemistry and Biophysics (1992), 295(1), 13-20
CODEN: ABBIA4; ISSN: 0003-9861
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Kidney, **composition**
Liver, **composition**
(**heme oxygenase**-2 homologous transcripts expression in, of human)
IT Testis, **composition**
(**heme oxygenase**-2 mRNA expression in, of human)

L6 ANSWER 9 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:56846 CAPLUS
DOCUMENT NUMBER: 118:56846
TITLE: In situ hybridization and immunohistochemical localization of heme oxygenase-2 mRNA and protein in normal rat brain: differential distribution of isozyme 1 and 2
AUTHOR(S): Ewing, James F.; Maines, Mahin D.
CORPORATE SOURCE: Med. Cent., Univ. Rochester, Rochester, NY, 14642, USA
SOURCE: Molecular and Cellular Neuroscience (1992), 3(6), 559-70
CODEN: MOCNED; ISSN: 1044-7431
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Brain, **composition**
(**heme oxygenase** isoenzymes 1 and 2 of, differential distribution of)
IT Nerve, **composition**
Neuroglia
(**heme oxygenase** isoenzymes 1 and 2 of, of brain, differential distribution of)

L6 ANSWER 10 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:51758 CAPLUS
DOCUMENT NUMBER: 118:51758
TITLE: Effect of calcium antagonists on hepatic heme oxygenase and metallothionein induction by lithium chloride in rats
AUTHOR(S): Arizono, K.; Fuji, H.; Nakano, M.; Ariyoshi, T.
CORPORATE SOURCE: Fac. Pharm. Sci., Nagasaki Univ., Nagasaki, 852, Japan
SOURCE: Lithium (1992), 3(4), 299-301
CODEN: LITHER; ISSN: 0954-1381
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Liver, **composition**
(**heme oxygenase** and metallothionein of, lithium induction of, calcium antagonists effect on)

=> d l6 ibib kwic 11-15
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, USPATFULL' - CONTINUE? (Y)/N:y

L6 ANSWER 11 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:2176 CAPLUS
DOCUMENT NUMBER: 118:2176
TITLE: Rat lung metallothionen and heme oxygenase gene expression following ozone and zinc oxide exposure

AUTHOR(S): Cosma, Greg; Fulton, Helen; DeFeo, Tony; Gordon, Terry
CORPORATE SOURCE: Med. Cent., New York Univ., New York, NY, 10016, USA
SOURCE: Toxicology and Applied Pharmacology (1992), 117(1), 75-80
CODEN: TXAPA9; ISSN: 0041-008X
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Lung, **composition**
(**heme oxygenase** and metallothionein genes of, expression of, ozone and zinc oxide effect on)

L6 ANSWER 12 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1992:508957 CAPLUS
DOCUMENT NUMBER: 117:108957
TITLE: Differential regulation of heme oxygenase isozymes by tin- and zinc-protoporphyrins: possible relevance to suppression of hyperbilirubinemia
AUTHOR(S): Maines, Mahin D.; Trakshel, G. Michael
CORPORATE SOURCE: Sch. Med., Univ. Rochester, Rochester, NY, USA
SOURCE: Biochimica et Biophysica Acta (1992), 1131(2), 166-74
CODEN: BBACAQ; ISSN: 0006-3002
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Adrenal gland, **composition**
Liver, **composition**
Testis, **composition**
(**heme oxygenase** isoenzymes of microsome of, tin- and zinc-protoporphyrins regulation of)

L6 ANSWER 13 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1992:171539 CAPLUS
DOCUMENT NUMBER: 116:171539
TITLE: Heme oxygenase is a positive acute-phase reactant in human Hep3B hepatoma cells
AUTHOR(S): Mitani, Kinuko; Fujita, Hiroyoshi; Kappas, Attallah; Sassa, Shigeru
CORPORATE SOURCE: Lab. Metab. Pharmacol., Rockefeller Univ. Hosp., New York, NY, 10021, USA
SOURCE: Blood (1992), 79(5), 1255-9
CODEN: BLOOAW; ISSN: 0006-4971
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Liver, **composition**
(**heme oxygenase** mRNA of human cell line of, in acute phase reaction)

L6 ANSWER 14 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:674071 CAPLUS
DOCUMENT NUMBER: 115:274071
TITLE: Immunochemical studies of heme oxygenase. Preparation and characterization of antibodies to chick liver heme oxygenase and their use in detecting and quantifying amounts of heme oxygenase protein
AUTHOR(S): Greene, Yvonne J.; Healey, John F.; Bonkovsky, Herbert L.
CORPORATE SOURCE: Med. Sch., Univ. Massachusetts, Worcester, MA, 01655, USA
SOURCE: Biochemical Journal (1991), 279(3), 849-54
CODEN: BIJOAK; ISSN: 0306-3275
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Brain, **composition**
Liver, **composition**
Spleen, **composition**

Testis, **composition**
(**heme oxygenase** 1 of, of chicken and mammals, detn. of)

L6 ANSWER 15 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:624292 CAPLUS
DOCUMENT NUMBER: 115:224292
TITLE: Retinoic acid can enhance the stimulation by thyroid hormone of heme oxygenase activity in the liver of thyroidectomized rats
AUTHOR(S): Smith, Terry J.; Drummond, George S.
CORPORATE SOURCE: Dep. Med., Albany Med. Coll., Albany, NY, 12208, USA
SOURCE: Biochimica et Biophysica Acta (1991), 1075(2), 119-22
CODEN: BBACAQ; ISSN: 0006-3002
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Liver, **composition**
(**heme oxygenase** of, thyroid hormones stimulation of, retinoate enhancement of)

=> d l6 ibib kwic 16-20
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, USPATFULL' - CONTINUE? (Y)/N:y

L6 ANSWER 16 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:554001 CAPLUS
DOCUMENT NUMBER: 115:154001
TITLE: Comparative photoactivity of tin and zinc porphyrin inhibitors of heme oxygenase: pronounced photolability of the zinc compounds
AUTHOR(S): Greenbaum, Nancy L.; Kappas, Attallah
CORPORATE SOURCE: Rockefeller Univ. Hosp., New York, NY, 10021, USA
SOURCE: Photochemistry and Photobiology (1991), 54(2), 183-92
CODEN: PHCBAP; ISSN: 0031-8655
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Liver, **composition**
(**heme oxygenase** of, tin and zinc porphyrins and light inhibition of)

L6 ANSWER 17 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:488245 CAPLUS
DOCUMENT NUMBER: 115:88245
TITLE: Degradation of heme by a soluble peptide of heme oxygenase obtained from rat liver microsomes by mild trypsinization
AUTHOR(S): Yoshida, Tadashi; Ishikawa, Kazunobu; Sato, Michihiko
CORPORATE SOURCE: Sch. Med., Yamagata Univ., Yamagata, 990-23, Japan
SOURCE: European Journal of Biochemistry (1991), 199(3), 729-33
CODEN: EJBCAI; ISSN: 0014-2956
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Liver, **composition**
(**heme oxygenase** of, heme degrdn. by catalytic domain of)

L6 ANSWER 18 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:469274 CAPLUS
DOCUMENT NUMBER: 115:69274
TITLE: Rapid induction of heme oxygenase 1 mRNA and protein by hyperthermia in rat brain: heme oxygenase 2 is not

a heat shock protein
AUTHOR(S): Ewing, J. F.; Maines, M. D.
CORPORATE SOURCE: Med. Cent., Univ. Rochester, Rochester, NY, 14642, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1991), 88(12), 5364-8
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Nerve, **composition**
(**heme oxygenase** of, of brain, heat effect on)

L6 ANSWER 19 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:466503 CAPLUS
DOCUMENT NUMBER: 115:66503
TITLE: Heme oxygenase activity and cytochrome P-450 content associated with induced metallothionein in the liver of rats treated with various metals
AUTHOR(S): Arizono, Koji; Okanari, Eiji; Ueno, Kiyoshi; Ariyoshi, Toshihiko
CORPORATE SOURCE: Fac. Pharm. Sci., Nagasaki Univ., Nagasaki, 852, Japan
SOURCE: Journal of Environmental Science and Health, Part A: Environmental Science and Engineering (1991), A26(6), 941-51
CODEN: JESEDU; ISSN: 0360-1226
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Liver, **composition**
(**heme oxygenase** and wt. of, metal-binding and nonbinding metallothioneins effect on)

L6 ANSWER 20 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:405817 CAPLUS
DOCUMENT NUMBER: 115:5817
TITLE: Heme oxygenase induction by cobalt chloride, Co-protoporphyrin IX, phenylhydrazine, and diamide: evidence for oxidative stress involvement
AUTHOR(S): Tomaro, Maria L.; Frydman, Judith; Frydman, Rosalia B.
CORPORATE SOURCE: Fac. Farm. Bioquim., Univ. Buenos Aires, Buenos Aires, 1113, Argent.
SOURCE: Archives of Biochemistry and Biophysics (1991), 286(2), 610-17
CODEN: ABBIA4; ISSN: 0003-9861
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Liver, **composition**
(**heme oxygenase** of, induction of, oxidative stress in)

=> d l6 ibib kwic 21-25
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, USPATFULL' - CONTINUE? (Y)/N:y

L6 ANSWER 21 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:181035 CAPLUS
DOCUMENT NUMBER: 114:181035
TITLE: Heterogeneity of heme oxygenase 1 and 2 isoenzymes. Rat and primate transcripts for isoenzyme 2 differ in number and size
AUTHOR(S): Trakshel, G. Michael; Ewing, James F.; Maines, Mahin D.
CORPORATE SOURCE: Sch. Med., Univ. Rochester, Rochester, NY, 14642, USA
SOURCE: Biochemical Journal (1991), 275(1), 159-64

CODEN: BIJOAK; ISSN: 0306-3275
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Brain, **composition**
Kidney, **composition**
Liver, **composition**
(**heme oxygenase** isoenzymes 1 and 2 of, of monkey and rat)

L6 ANSWER 22 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:79348 CAPLUS
DOCUMENT NUMBER: 114:79348
TITLE: Induction of heme oxygenase mRNA by cobalt protoporphyrin in rat liver
AUTHOR(S): Smith, Terry J.; Haque, Shahid; Drummond, George S.
CORPORATE SOURCE: Sch. Med. Biomed., State Univ. New York, Buffalo, NY, USA
SOURCE: Biochimica et Biophysica Acta (1991), 1073(1), 221-4
CODEN: BBACAQ; ISSN: 0006-3002
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Liver, **composition**
(**heme oxygenase**-specifying mRNA of, cobalt protoporphyrin effect on)

L6 ANSWER 23 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:627074 CAPLUS
DOCUMENT NUMBER: 113:227074
TITLE: Structural studies on bovine spleen heme oxygenase. Immunological and structural diversity among mammalian heme oxygenase enzymes
AUTHOR(S): Schacter, Brent A.; Cripps, Val; Troxler, Robert F.; Offner, Gwynneth D.
CORPORATE SOURCE: Dep. Med., Univ. Manitoba, Winnipeg, MB, R3E 0V9, Can.
SOURCE: Archives of Biochemistry and Biophysics (1990), 282(2), 404-12
CODEN: ABBIA4; ISSN: 0003-9861
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Spleen, **composition**
(**heme oxygenase** of bovine, structure of, human and other mammalian enzymes comparison with, evolution in relation to)

L6 ANSWER 24 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:526271 CAPLUS
DOCUMENT NUMBER: 113:126271
TITLE: Effect of heme arginate administration on blood pressure in spontaneously hypertensive rats
AUTHOR(S): Levere, Richard D.; Martasek, Pavel; Escalante, Bruno; Schwartzman, Michal L.; Abraham, Nader G.
CORPORATE SOURCE: Dep. Med., New York Med. Coll., Valhalla, NY, 10595, USA
SOURCE: Journal of Clinical Investigation (1990), 86(1), 213-19
CODEN: JCINAO; ISSN: 0021-9738
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Liver, **composition**
(**heme oxygenase** and cytochrome P 450 of, heme arginate effect on, hypotensive effects in relation to)

L6 ANSWER 25 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:403676 CAPLUS
DOCUMENT NUMBER: 113:3676

TITLE: Developmental expression of heme oxygenase isozymes in rat brain. Two HO-2 mRNAs are detected
AUTHOR(S): Sun, Yi; Rotenberg, Mitch O.; Maines, Mahin D.
CORPORATE SOURCE: Sch. Med., Univ. Rochester, Rochester, NY, 14642, USA
SOURCE: Journal of Biological Chemistry (1990), 265(14), 8212-17
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Brain, **composition**
Spleen, **composition**
(**heme oxygenase**-specifying mRNA of, in development)

=> d l6 ibib kwic 26-30
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, USPATFULL' - CONTINUE? (Y)/N:y

L6 ANSWER 26 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:232970 CAPLUS
DOCUMENT NUMBER: 112:232970
TITLE: Mechanism of synergistic induction of hepatic heme oxygenase by glutethimide and iron: studies in cultured chick embryo liver cells
AUTHOR(S): Cable, E.; Greene, Y.; Healey, J.; Evans, C. O.; Bonkovsky, H.
CORPORATE SOURCE: Dep. Biochem., Emory Univ., Atlanta, GA, 30322, USA
SOURCE: Biochemical and Biophysical Research Communications (1990), 168(1), 176-81
CODEN: BBRCA9; ISSN: 0006-291X
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Liver, **composition**
(**heme oxygenase** of, glutethimide and iron synergistic induction of, heme dependence of)

L6 ANSWER 27 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:194224 CAPLUS
DOCUMENT NUMBER: 112:194224
TITLE: Purification and characterization of hepatic heme oxygenase from chick liver. Comparison of the avian and mammalian enzymes
AUTHOR(S): Bonkovsky, Herbert L.; Healey, John F.; Pohl, J.
CORPORATE SOURCE: Winship Cancer Cent., Emory Univ., Atlanta, GA, 30322, USA
SOURCE: European Journal of Biochemistry (1990), 189(1), 155-66
CODEN: EJBCAI; ISSN: 0014-2956
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Liver, **composition**
(**heme oxygenase** of avian, purifn. and characterization of)

L6 ANSWER 28 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:193483 CAPLUS
DOCUMENT NUMBER: 112:193483
TITLE: Profile of metal-binding proteins and heme oxygenase in red carp treated with heavy metals, pesticides and surfactants
AUTHOR(S): Ariyoshi, Toshihiko; Shiiba, Seiichi; Hasegawa, Hiroyuki; Arizono, Koji
CORPORATE SOURCE: Fac. Pharm. Sci., Nagasaki Univ., Nagasaki, 852, Japan

SOURCE: Bulletin of Environmental Contamination and Toxicology (1990), 44(4), 643-9
CODEN: BECTA6; ISSN: 0007-4861
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Hepatopancreas
Kidney, **composition**
(**heme oxygenase** and metal-binding proteins of, of carp, heavy metals and pesticides and surfactants effect on)

L6 ANSWER 29 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:174478 CAPLUS
DOCUMENT NUMBER: 112:174478
TITLE: Expression of heme oxygenase in hemopoiesis
AUTHOR(S): Abraham, Nader G.; Mitrione, Steve M.; Hodgson, W. John B.; Levere, Richard D.; Shibahara, Shigeki
CORPORATE SOURCE: Dep. Med., New York Med. Coll., Valhalla, NY, 10595, USA
SOURCE: Advances in Experimental Medicine and Biology (1988), 241(Mol. Biol. Hemopoiesis), 97-116
CODEN: AEMBAP; ISSN: 0065-2598
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Bone marrow, **composition**
Brain, **composition**
Heart, **composition**
Intestine, **composition**
Kidney, **composition**
Spleen, **composition**
(**heme oxygenase** of microsome of human)
IT Liver, **composition**
(**heme oxygenase** of microsome of, of human and rat)

L6 ANSWER 30 OF 126 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:18102 CAPLUS
DOCUMENT NUMBER: 112:18102
TITLE: In vitro inhibition of adult rat intestinal heme oxygenase by metalloporphyrins
AUTHOR(S): Vreman, Hendrik J.; Gillman, Michael J.; Stevenson, David K.
CORPORATE SOURCE: Sch. Med., Stanford Univ., Stanford, CA, 94305, USA
SOURCE: Pediatric Research (1989), 26(4), 362-5
CODEN: PEREBL; ISSN: 0031-3998
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Intestine, **composition**
Liver, **composition**
Spleen, **composition**
(**heme oxygenase** of, metalloporphyrin inhibition of, light in relation to)

=> d his

(FILE 'HOME' ENTERED AT 19:00:52 ON 24 MAY 2003)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 19:01:10 ON 24 MAY 2003
L1 102 S (PROCYANIDOL? OR FLAVANOL?) (N) OLIGOMER
L2 24806 S ((HSP OR HEAT SHOCK PROTEIN) (N) 32) OR HSP32 OR HEME OXYGENA
L3 1 S L1 AND L2

FILE 'LIFESCI' ENTERED AT 19:22:14 ON 24 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 19:22:14 ON 24 MAY 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 19:22:14 ON 24 MAY 2003

FILE 'NAPRALERT' ENTERED AT 19:22:14 ON 24 MAY 2003
COPYRIGHT (C) 2003 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 19:22:14 ON 24 MAY 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'NUTRACEUT' ENTERED AT 19:22:14 ON 24 MAY 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PASCAL' ENTERED AT 19:22:14 ON 24 MAY 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 19:22:14 ON 24 MAY 2003
COPYRIGHT (C) 2003 WIPO

FILE 'PHARMAML' ENTERED AT 19:22:14 ON 24 MAY 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 19:22:14 ON 24 MAY 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 19:22:14 ON 24 MAY 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'SCISEARCH' ENTERED AT 19:22:14 ON 24 MAY 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'TOXCENTER' ENTERED AT 19:22:14 ON 24 MAY 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 19:22:14 ON 24 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 19:22:14 ON 24 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l4 and cosmetic
L12 26 L4 AND COSMETIC

=> d l12 ibib kwic 1-5

L12 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:475516 CAPLUS
DOCUMENT NUMBER: 133:94311
TITLE: **Cosmetic** or **dermatological** composition containing an active principle stimulating **HSP 32** protein synthesis in the skin
INVENTOR(S): Nizard, Carine; Moreau, Marielle; Bonte, Frederic
PATENT ASSIGNEE(S): Parfums Christian Dior, Fr.
SOURCE: PCT Int. Appl., 19 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040215	A1	20000713	WO 1999-FR3310	19991229
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2787996	A1	20000707	FR 1998-16641	19981230
FR 2787996	B1	20020510		
EP 1140000	A1	20011010	EP 1999-964734	19991229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: FR 1998-16641 A 19981230
WO 1999-FR3310 W 19991229
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI **Cosmetic** or **dermatological** composition containing an active principle stimulating **HSP 32** protein synthesis in the skin

AB The invention concerns a dermatol. or cosmetol. compn., characterized in that it contains at least a compd. capable of activating **HSP 32** endogenetic synthesis or a functional peptide fragment of such a protein with pharmaceutically and/or cosmetol. acceptable carriers. The invention also concerns the use of a compd. selected from the group consisting of procyanidolic oligomers (PCO) and their derivs., caffeic acid esters and their derivs. and mixts. of said compds., for prepg. a compn. designed to activate endogenetic synthesis of **HSP 32** or a functional peptide fragment of such a protein. PCO stimulated the synthesis of **HSP 32** in presence of UV by 204%. A **cosmetic** compn. contained PCO from raisin seed 0.5, ceramide-3 0.12, glycerin 2, octyl methoxycinnamate 7.5, Parsol-1789 2, tocopherol acetate 0.2, excipients and perfume q.s. 100%.

ST heat shock protein stimulant **cosmetic**; procyanidolic oligomer **cosmetic** methoxycinnamate UV

IT Heat-shock proteins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**HSP 32**; **cosmetic** or dermatol. compn. contg. active principle stimulating **HSP 32** protein synthesis in skin)

IT Cosmetics
(antiaging; **cosmetic** or dermatol. compn. contg. active principle stimulating **HSP 32** protein synthesis in skin)

IT Margosa (Melia azadirachta)
Sunscreens
Radical scavengers
RL: BIOL (Biological study)
(**cosmetic** or dermatol. compn. contg. active principle stimulating **HSP 32** protein synthesis in skin)

IT Saponins
Tocopherols
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** or dermatol. compn. contg. active principle stimulating **HSP 32** protein synthesis in skin)

IT Cosmetics

(creams, wrinkle-preventing; **cosmetic** or dermatol. compn. contg. active principle stimulating **HSP 32** protein synthesis in skin)

IT Ketones, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(diketones, unsatd., curcuminoids; **cosmetic** or dermatol. compn. contg. active principle stimulating **HSP 32** protein synthesis in skin)

IT Centella asiatica
Loquat (Eriobotrya japonica)
(ext., **cosmetic** or dermatol. compn. contg. active principle stimulating **HSP 32** protein synthesis in skin)

IT Coleus barbatus
Potentilla recta
(ext.; **cosmetic** or dermatol. compn. contg. active principle stimulating **HSP 32** protein synthesis in skin)

IT Flavones
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(isoflavones; **cosmetic** or dermatol. compn. contg. active principle stimulating **HSP 32** protein synthesis in skin)

IT Oligomers
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(procyanidolic; **cosmetic** or dermatol. compn. contg. active principle stimulating **HSP 32** protein synthesis in skin)

IT 50-81-7, Vitamin c, biological studies 59-92-7, biological studies 60-18-4D, Tyrosine, malyl(sic) deriv. 331-39-5D, Caffeic acid, esters 446-72-0, Genistein 458-37-7, Curcumine 471-53-4, 18.beta.-Glycyrrhetinic acid 476-66-4, Ellagic acid 485-72-3, Formononetin 486-66-8, Daidzein 10043-83-1, Magnesium phosphate 61276-16-2, Oraposide 71276-50-1 115346-09-3, Forskolin E 216210-47-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** or dermatol. compn. contg. active principle stimulating **HSP 32** protein synthesis in skin)

L12 ANSWER 2 OF 26 IFIPAT COPYRIGHT 2003 IFI

AN 10111320 IFIPAT;IFIUDB;IFICDB

TITLE: PROCESS FOR THE EXTRACTION OF AN ACTIVE PRINCIPLE FROM LEAVES OF OLEA EUROPAEA TO PROMOTE THE SYNTHESIS OF STRESS PROTEINS, OBTAINED ACTIVE PRINCIPLE; SOLUBILIZATION, DECANATION, FILTRATION, STERILIZATION; COSMETICS FOR GUARDING AGAINST EFFECTS OF ULTRAVIOLET RADIATION

INVENTOR(S): Paufique; Jean-Jacques, Objat, FR

PATENT ASSIGNEE(S): Unassigned

AGENT: YOUNG & THOMPSON, 745 SOUTH 23RD STREET 2ND FLOOR, ARLINGTON, VA, 22202

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2002054927	A1	20020509
APPLICATION INFORMATION:	US 2001-947572		20010907

NUMBER	DATE

PRIORITY APPLN. INFO.: FR 2000-11398 20000907
FAMILY INFORMATION: US 2002054927 20020509
DOCUMENT TYPE: Utility
Patent Application - First Publication
FILE SEGMENT: CHEMICAL
APPLICATION
NUMBER OF CLAIMS: 5 6 Figure(s).

DESCRIPTION OF FIGURES:
FIG. 1, a recapitulative table of the effects of temperature on the production of stress proteins HSP 70,
FIG. 2, a table of the effects of the active principle according to the present invention on the production of stress proteins HSP 70 in human keratinocyte and fibroblast cultures, with and without thermal treatment,
FIG. 3, a table of the effects-dosages of the active principle on the induction of stress proteins HSP 70,
FIG. 4, a recapitulative table of the effects of temperature on the production of stress proteins **HSP 32**,
FIG. 5, a table of the effects of the active principle according to the present invention on the production of stress proteins **HSP 32** in human keratinocyte and fibroblast cultures, with and without thermal treatment, and
FIG. 6, a table of the effects-dosages of the active principle on the induction of stress proteins **HSP 32**.

AB . . . to limit the presence of microorganisms, of total mesophilic flora, of yeast, and of molds. The invention also covers a **cosmetic** composition and a process for improving the production of stress proteins.

GI . . .
of stress proteins HSP 70,
FIG. 4, a recapitulative table of the effects of temperature on the production of stress proteins **HSP 32**,
FIG. 5, a table of the effects of the active principle according to the present invention on the production of stress proteins **HSP 32** in human keratinocyte and fibroblast cultures, with and without thermal treatment, and
FIG. 6, a table of the effects-dosages of the active principle on the induction of stress proteins **HSP 32**.

ACLM 3. **Cosmetic** composition to increase the production of stress proteins and to guard against the effects of ultraviolet radiation, characterized in that. . .
. . . 4. Process to increase the production of stress proteins characterized in that there is preventatively disposed on the skin a **cosmetic** composition according to claim 3 in an amount of at least 0.1% of active principle.

L12 ANSWER 3 OF 26 IFIPAT COPYRIGHT 2003 IFI
AN 3686667 IFIPAT;IFIUDB;IFICDB
TITLE: USE OF SUNSCREEN COMBINATIONS COMPRISING, AS ESSENTIAL CONSTITUENT, 4,4'-DIARYLBUTADIENES AS PHOTOSTABLE UV FILTERS IN **COSMETIC** AND PHARMACEUTICAL PREPARATIONS; WITH ONE OR MORE OF: DIBENZOYLMETHANES, TRIAZINE DERIVATIVES, BENZOTRIAZOLE, SILOXANES AND/OR TETRAHYDROXYBENZOPHENONE; PHOTOSTABLE; UV FILTERS ABSORPTION MAXIMA WITHIN 280 TO 400 NM RANGE (BOTH UVA AND UVB WAVERANGES)
INVENTOR(S): Habeck; Thorsten, Meckenheim, DE
Heidenfelder; Thomas, Romerberg, DE
Wunsch; Thomas, Speyer, DE
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Ludwigshafen, DE
PRIMARY EXAMINER: Dodson, Shelley A
AGENT: Keil & Weinkauf

	NUMBER	PK	DATE
PATENT INFORMATION:	US 6391289		20020521
APPLICATION INFORMATION:	US 2001-805238		20010314
EXPIRATION DATE:	14 Mar 2021		

	NUMBER	DATE
PRIORITY APPLN. INFO.:	DE 2000-10012413	20000315
FAMILY INFORMATION:	US 6391289	20020521
DOCUMENT TYPE:	UTILITY	
FILE SEGMENT:	CHEMICAL	
	GRANTED	
NUMBER OF CLAIMS:	12	

TI USE OF SUNSCREEN COMBINATIONS COMPRISING, AS ESSENTIAL CONSTITUENT, 4,4'-DIARYLBUTADIENES AS PHOTOSTABLE UV FILTERS IN **COSMETIC** AND PHARMACEUTICAL PREPARATIONS; WITH ONE OR MORE OF: DIBENZOYLMETHANES, TRIAZINE DERIVATIVES, BENZOTRIAZOLE, SILOXANES AND/OR TETRAHYDROXYBENZOPHENONE; PHOTOSTABLE; UV FILTERS ABSORPTION MAXIMA.

AB . . . chosen from a group defined in detail in the Description of the Invention below as photostable UV filter combination in **cosmetic** and pharmaceutical preparations for protecting the human epidermis or human hair against UV radiation, specifically in the range from 320.

ECLM . . . solar rays, comprising application, to the human skin or human hair to be protected, of an effective amount of a **cosmetic** or pharmaceutical preparation of sunscreen combinations comprising A) compounds absorbing essentially in the UV-A region and B) further compounds absorbing. . . 1,4-DI((HO3S-)2-BENZIMIDAZOL-2-YL)-)BENZENE VII

Bf) the benzotriazole derivative of the formula VIII

2-((2-(HO-),3-(Me-Si(-Me)2-O-Si(-CH3)(-O-Si(-Me)2-Me)-CH2-CH(-CH3)-CH2-),5-(CH3-)PHENYL)-)-2H-BENZOTRIAZOLE VIII

Bg) o,o',p,p'-tetrahydroxybenzophenone of the formula IX

HO-(3-(**HO**-)-**1**,4-PHENYLENE)-CO-(2-(**HO**-)-**1**,4-PHENYLENE)-OH IX and

Bh) an organosiloxane benzalmalonate of the formula Xa

V1-Si(-CH3)2-O-(Si(-CH3)2-O)t-(Si(-CH3)(-V1')-O)u-Si(-CH3)2-V1, Xa

in which V1 ' is the group

. . . UV filters, optionally together with further compounds which absorb in the UV region and which are known per se for **cosmetic** and pharmaceutical preparations.

ACLM 7. A **cosmetic** or pharmaceutical preparation comprising sunscreen combinations for the protection of the human epidermis or human hair against UV light in. . . and u is a value from 1 to 20 when V1 =CH3 and/or V2 =CH3, as photostable UV filters in **cosmetic** and pharmaceutical preparations for protecting human skin or human hair against solar rays, optionally together with further compounds which absorb in the UV region and which are known per se for **cosmetic** and pharmaceutical preparations.

8. A **cosmetic** or pharmaceutical preparation comprising sunscreen combinations as claimed in claim 7, wherein the sunscreen

combinations comprise compounds of the formula. . .
9. A **cosmetic** or pharmaceutical preparation comprising sunscreen combinations as claimed in claim 7, wherein the sunscreen combinations comprise, as constituent Bb), triazine. . .
10. A **cosmetic** or pharmaceutical preparation comprising sunscreen combinations as claimed in claim 7, wherein the sunscreen combinations comprise, as constituent Bb), triazine. . .
11. A **cosmetic** or pharmaceutical preparation comprising sunscreen combinations as claimed in claim 7, wherein the sunscreen combinations comprise the constituent of the. . .
12. A **cosmetic** or pharmaceutical preparation comprising sunscreen combinations as claimed in claim 7, wherein the sunscreen combinations, in addition to B) comprise. . .

L12 ANSWER 4 OF 26 IFIPAT COPYRIGHT 2003 IFI

AN	3647461 IFIPAT;IFIUDB;IFICDB
TITLE:	**COSMETIC** COMPOSITIONS CONTAINING SUBSTITUTED IMINODIBENZYL OR FLUORENE DERIVATIVES; 5-((2-METHYL-3-CHLOROPHENYL)AMINOCARBONYL)-10,11-DIHYDRO-5H -DIBENZ(B,F) AZEPINE, FOR EXAMPLE; FOR CONTROL OF SEBUM SECRETION FROM SEBOCYTES, IMPROVED OIL CONTROL AND IMPROVED FEEL
INVENTOR(S):	Bajor; John Steven, Ramsey, NJ Pocalyko; David Joseph, Wayne, NJ
PATENT ASSIGNEE(S):	Unilever Home and Personal Care USA, division of Conopco, Inc., Greenwich, CT
PRIMARY EXAMINER:	Hartley, Michael G
ASSISTANT EXAMINER:	Willis, Michael A
AGENT:	Plotkin, Ellen

	NUMBER	PK	DATE
PATENT INFORMATION:	US 6355687		20020312
APPLICATION INFORMATION:	US 2001-873159		20010601
EXPIRATION DATE:	1 Jun 2021		

	NUMBER	DATE
PRIORITY APPLN. INFO.:	US 2000-215648P	20000630 (Provisional)
FAMILY INFORMATION:	US 6355687	20020312
DOCUMENT TYPE:	UTILITY	
FILE SEGMENT:	CHEMICAL GRANTED	
NUMBER OF CLAIMS:	4	

TI **COSMETIC** COMPOSITIONS CONTAINING SUBSTITUTED IMINODIBENZYL OR FLUORENE DERIVATIVES; 5-((2-METHYL-3-CHLOROPHENYL)AMINOCARBONYL)-10,11-DIHYDRO-5H -DIBENZ(B,F) AZEPINE, FOR EXAMPLE; FOR CONTROL OF SEBUM SECRETION FROM SEBOCYTES, IMPROVED. . .

AB **Cosmetic** methods and compositions containing selected iminodibenzyl or fluorene derivatives. When used for skin or hair care, the inventive compositions provide. . .

ECLM 1. A **cosmetic** composition comprising: (i) from about 0.001% to about 50% of a substituted iminodibenzyl compound

5-(R-CO-)-10,11-DIHYDRO-5H-DIBENZ(b,f)AZEPINE

or a substituted fluorine compound

9-(R-CO-)FLUORENE

selected from the group consisting of compounds A through H as follows:

ComH-CH(-CH3)-(1,3-PHENYLENE)-NH- A

F3C-O-(1,4-PHENYLENE)-NH- B

HO-(1,4-PHENYLENE)-NH-

C
(2-(H3C-),3-(Cl-)PHENYL)-NH- D
(2-(H3C-),4-(H3C-O-)PHENYL)-NH- E
(4-(HO-),4-((4-(Cl-)PHENYL)-)PIPERIDIN-1-YL)- F
(4-(HO-),4-(PHENYL-)PIPERIDIN-1-YL)- G
HO-CH2-CH2-N(-CH2-CH2-CH3)-
10,11-DIHYDRO-5H-BENZ(b,f)AZEPIN-1-YL-CO-N-(1,3-PHENYLENE)-CH(-OH)-CH3 A
10,11-DIHYDRO-5H-BENZ(b,f)AZEPIN-1-YL-CO-N-(1,4-PHENYLENE)-O-CF3 B
10,11-DIHYDRO-5H-BENZ(b,f)AZEPIN-1-YL-CO-N-(1,4-PHENYLENE)-OH C
10,11-DIHYDRO-5H-BENZ(b,f)AZEPIN-1-YL-CO-N-(3-(Cl-)-
. . .

ACLM 4. A **cosmetic** method of reducing sebum secretion from sebocytes, the method comprising applying to the skin the composition of claim 1.

L12 ANSWER 5 OF 26 IFIPAT COPYRIGHT 2003 IFI

AN	3461582 IFIPAT;IFIUDB;IFICDB		
TITLE:	SUGAR COMPOUNDS, GELLING AGENTS, GELLING AGENT COMPOSITIONS PROCESSES FOR THE PREPARATION OF THEM, AND GEL COMPOSITIONS; REACTING SORBITOL OR XYLITOL WITH BENZALDEHYE IN PRESENCE OF ACID CATALYST		
INVENTOR(S):	Ando; Kenshi, Uji, JP Kobayashi; Toshiaki, Nara, JP Nomoto; Harutomo, Kyoto, JP		
PATENT ASSIGNEE(S):	New Japan Chemical Co., Ltd., JP		
PRIMARY EXAMINER:	Nutter, Nathan M		
AGENT:	Larson & Taylor, PLC		

	NUMBER	PK	DATE	
PATENT INFORMATION:	US 6187842		20010213	
	WO 9823604		19980604	
APPLICATION INFORMATION:	US 1999-297676		19990506	
	WO 1997-JP4280		19971121	
			19990506	PCT 371 date
			19990506	PCT 102(e) date
EXPIRATION DATE:	21 Nov 2017			

	NUMBER	DATE
PRIORITY APPLN. INFO.:	JP 1996-334559	19961128
	JP 1997-286169	19971001
FAMILY INFORMATION:	US 6187842	20010213
DOCUMENT TYPE:	UTILITY	
FILE SEGMENT:	CHEMICAL	
	GRANTED	
MICROFILM REEL NO:	010034 FRAME NO: 0551	
NUMBER OF CLAIMS:	23	

ECLM . . . sugar compound represented by the formula (1) or the formula (2)

2-((3-R2,4-R1-PHENYL)-),4-(HO-CH2-(CH(-OH))p-),5-(HO-),
6-(HO-CH2-)-1,3-DIOXANE 1

2-((3-R2,4-R1-PHENYL)-),4-(HO-CH2-(CH(-OH))p-CH(-OH)-
),5-(**HO**-)-**1**,3-DIOXANE
2

wherein R1 and R2 are the same or different and each represents an alkyl group having 1 to. . .

ACLM 12. The gel according to claim 6 further comprising an active component for **cosmetic** compositions.

=> d l12 ibib kwic 6-10

L12 ANSWER 6 OF 26 IFIPAT COPYRIGHT 2003 IFI
AN 3419927 IFIPAT;IFIUDB;IFICDB
TITLE: **COSMETIC** AND COSMECEUTICAL COMPOSITIONS; MIXTURE CONTAINING NOR-DIHYDROGUAIARETIC ACID AND NIACINAMIDE, CARRIERS AND ADJUVANTS FOR REPAIR OF DNA DAMAGE CAUSED BY RADIATION EXPOSURE
INVENTOR(S): Oren-Riklis legal representative; by Liatt, 14 Smats St., Tel Aviv, IL
Riklis deceased; Emanuel, late of Beer-Sheva, IL
Riklis legal representative; by Eitan, 33 Dam Hamacabim St., Tel Aviv, IL
Riklis legal representative; by Eran, 10 Nelchet St., Tel Aviv 65215, IL
Riklis legal representative; by Ruth, 10 Bar Kochba Street, 84231 Beer-Sheva, IL
PATENT ASSIGNEE(S): Unassigned
PRIMARY EXAMINER: Dodson, Shelley A
AGENT: Evenson, McKeown, Edwards & Lenahan, P.L.L.C.

	NUMBER	PK	DATE	
PATENT INFORMATION:	US 6149896		20001121	
	WO 9716155		19970509	
APPLICATION INFORMATION:	US 1999-68080		19990205	
	WO 1996-IL135		19961030	
			19990205	PCT 371 date
			19990205	PCT 102(e) date

EXPIRATION DATE: 30 Oct 2016

	NUMBER	DATE
PRIORITY APPLN. INFO.:	IL 1995-115851	19951102
FAMILY INFORMATION:	US 6149896	20001121

DOCUMENT TYPE: UTILITY
FILE SEGMENT: CHEMICAL
GRANTED
NUMBER OF CLAIMS: 8
GRAPHICS INFORMATION: 3 Drawing Sheet(s), 3 Figure(s).
TI **COSMETIC** AND COSMECEUTICAL COMPOSITIONS; MIXTURE CONTAINING NOR-DIHYDROGUAIARETIC ACID AND NIACINAMIDE, CARRIERS AND ADJUVANTS FOR REPAIR OF DNA DAMAGE CAUSED BY RADIATION. . .
AB **Cosmetic** and cosmeceutical compositions which enhance repair of damage caused to human DNA caused by excessive exposure to sunlight or to. . .
ECLM D R A W I N G

1. A **cosmetic** and cosmeceutical composition for DNA repair of damages caused by excessive sun exposure or exposure to any other radiation causing. . . DNA disruption, or modification which comprises in combination an effective quantity of nor-dihydroguiaretic acid (NDGA) of the formula

HO-(2-(**HO**-)-**1**,4-PHENYLENE)-CH2-CH(-CH3)-CH(-CH3)-CH2-
(2-(HO-)-4,1-PHENYLENE)-OH NDGA

and niacinamide, with conventional carriers, adjuvants or auxiliaries.

L12 ANSWER 7 OF 26 IFIPAT COPYRIGHT 2003 IFI
AN 3405330 IFIPAT;IFIUDB;IFICDB

TITLE: TOCOPHEROL ESTERS AND THEIR **COSMETIC** AND PHARMACEUTICAL USES; SKIN DISORDERS

INVENTOR(S): Bonte; Frederic, Orleans, FR
Saunois; Alex, Orleans, FR

PATENT ASSIGNEE(S): LVMH Recherche, Paris, FR

PRIMARY EXAMINER: Dentz, Bernard

AGENT: Meyer, Jerald L.
Nath & Associates PLLC
Nath, Gary M.

	NUMBER	PK	DATE	
PATENT INFORMATION:	US 6136851		20001024	
	WO 9851679		19981119	
APPLICATION INFORMATION:	US 1999-423513		19991110	
	WO 1998-FR958		19980514	
			19991110	PCT 371 date
			19991110	PCT 102(e) date

EXPIRATION DATE: 14 May 2018

	NUMBER	DATE
PRIORITY APPLN. INFO.:	FR 1997-5907	19970514
FAMILY INFORMATION:	US 6136851	20001024

DOCUMENT TYPE: UTILITY
FILE SEGMENT: CHEMICAL
GRANTED
MICROFILM REEL NO: 010477 FRAME NO: 0921
NUMBER OF CLAIMS: 22
GRAPHICS INFORMATION: 1 Drawing Sheet(s), 1 Figure(s).

TI TOCOPHEROL ESTERS AND THEIR **COSMETIC** AND PHARMACEUTICAL USES; SKIN DISORDERS

AB . . . the sum m+n+p+q is limited to integers in the range 0 to 4. The ester can be used for preparing **cosmetic** or pharmaceutical, in particular **dermatological**, compositions having activity against radicals, against inflammation, favoring differentiation of keratinocytes, improving skin moisturizing, improving skin grain fineness, and having. . .

ECLM . . . represents a chain of the form: --Bm --Cn --Bp --Cq --H in which: B is the following group:

-CO-(6-(**HO**-)-**1**,3-PHENYLENE)-O-

C is the following group:

-CO-(5-(**HO**-)-**1**,2-PHENYLENE)-O-

and in which the indices m, n, p, and q are respective integers lying in the range 0 to. . .

ACLM 7. A composition selected from the group consisting of a **cosmetic** and a pharmaceutical composition comprising as an active ingredient at least one ester as defined in claim 1, optionally in. . .
18. A method of **cosmetic** skin care comprising delivering topically to the skin of a human being a cosmetically effective amount of at least one. . .
19. A method of **cosmetic** care for performing a **cosmetic** care selected from the group consisting of avoiding or lowering the harmful effects of free radicals on the skin, for. . .
20. The **cosmetic** method of claim 19, wherein said ester is present in a composition containing said ester at a concentration ranging between. . .

L12 ANSWER 8 OF 26 IFIPAT COPYRIGHT 2003 IFI
AN 3253826 IFIPAT;IFIUDB;IFICDB

TITLE: **COSMETIC** COMPOSITION WITH POLYMER-BOUND BENZOPHENONE CHROMOPHORES; A MALEIC ANHYDRIDE-OLEFIN COPOLYMER WITH A BENZOPHENONE COMPOUND SUCH AS 2-HYDROXY,4-(2-HYDROXYETHOXY)-BENZOPHENONE BONDED VIA ESTER LINKAGE TO THE POLYMER BACKBONE; WATER RESISTANT, SKIN COMPATIBLE SUNSCREEN

INVENTOR(S): Keller; Harald, Ludwigshafen, DE
Sperling-Vietmeier; Karin, Neustadt, DE
Westenfelder; Horst, Neustadt, DE

PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Ludwigshafen, DE

PRIMARY EXAMINER: Webman, Edward J

AGENT: Keil & Weinkauf

	NUMBER	PK	DATE
PATENT INFORMATION:	US 6001337		19991214
APPLICATION INFORMATION:	US 1997-916392		19970822
EXPIRATION DATE:	22 Aug 2017		
FAMILY INFORMATION:	US 6001337		19991214

DOCUMENT TYPE: UTILITY
CERTIFICATE OF CORRECTION

CORRECTION DATE: 22 Aug 2000

FILE SEGMENT: CHEMICAL
GRANTED

MICROFILM REEL NO: 008772 FRAME NO: 0227

NUMBER OF CLAIMS: 3

TI **COSMETIC** COMPOSITION WITH POLYMER-BOUND BENZOPHENONE CHROMOPHORES; A MALEIC ANHYDRIDE-OLEFIN COPOLYMER WITH A BENZOPHENONE COMPOUND SUCH AS 2-HYDROXY,4-(2-HYDROXYETHOXY)-BENZOPHENONE BONDED VIA ESTER LINKAGE. . .

AB **Cosmetic** compositions contain a polymer with the repeating structural unit (I)

FIG-01

where the radicals have the meanings. . .

ECLM 1. A **cosmetic** composition comprising a polymer with the repeating structural unit (I)

-(CH(-COO-R1)-CH(-COO-R2)-CH2-CH(-X-R3))n- (I)

where R1 is

-(CH2-CH2-O)y-(3-(**HO**-)-**1**,3-PHENYLENE)-CO-C6H5,

wherein y is 0 to 6, R2 is hydrogen, an alkali metal ion, ammonium or a group as. . .

ACLM 2. The **cosmetic** composition defined in claim 1, wherein R3 is C19 H39 and X is CH.

3. The **cosmetic** composition defined in claim 1, wherein R3 is C16 -C22 -alkyl.

L12 ANSWER 9 OF 26 IFIPAT COPYRIGHT 2003 IFI

AN 2742611 IFIPAT;IFIUDB;IFICDB

TITLE: CARBOXYLIC POLYSACCHARIDE DERIVATIVES; **COSMETIC**

INVENTOR(S): Callegaro, Lanfranco, Padua, IT
Romeo, Aurelio, Rome, IT
Toffano, Gino, Padua, IT

PATENT ASSIGNEE(S): Fidia SpA, Abano Terme, IT

PRIMARY EXAMINER: Kulkosky, Peter F

AGENT: Birch, Stewart, Kolasch & Birch

	NUMBER	PK	DATE

	NUMBER	PK	DATE
PATENT INFORMATION:	US 5538730		19960723
APPLICATION INFORMATION:	US 1994-216858		19940324
EXPIRATION DATE:	23 Jul 2013		

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
CONTINUATION OF:	US 1992-944231	19920914	ABANDONED

	NUMBER	DATE
PRIORITY APPLN. INFO.:	IT 1991-PD160	19910913
FAMILY INFORMATION:	US 5538730	19960723
DOCUMENT TYPE:	UTILITY	
FILE SEGMENT:	CHEMICAL	
	GRANTED	
NUMBER OF CLAIMS:	26	

TI CARBOXYLIC POLYSACCHARIDE DERIVATIVES; **COSMETIC**

AB . . . are acylamino groups. Salts of these copolymers are also disclosed. The products of the invention are particularly useful in the **cosmetic** field.

ECLM 1. A copolymer of the formula:

-((3-S',4-(**HO**-),**6**-R-TETRAHYDROPYRAN-5,2-YLENE)-O)x-

YLENE)y-

wherein the bonds are Beta (1 -> 4) between the glucoside units, the degree of polymerization referred to. . .

ACLM 20. A **cosmetic** composition which comprises the copolymer or salt of claim 18, and a cosmetically acceptable excipient.

21. A **cosmetic** composition which comprises the copolymer or salt of claim 19, and a cosmetically acceptable excipient.

25. A **cosmetic** article containing a copolymer or a salt thereof according to claim 1.

26. The **cosmetic** article according to claim 25, which is a cream, ointment, or lotion for **topical** use.

L12 ANSWER 10 OF 26 IFIPAT COPYRIGHT 2003 IFI

AN	2541032 IFIPAT;IFIUDB;IFICDB
TITLE:	**COSMETIC** COMPOSITION; DIACYLGLYCEROLS AS CHEMICAL ACTIVATORS OF PROTEIN KINASE C ENZYMES FOR INDUCING AND INCREASING HAIR GROWTH
INVENTOR(S):	Green, Martin R, Buckingham, GB
PATENT ASSIGNEE(S):	Unilever Patent Holdings BV, Rotterdam, NL
PRIMARY EXAMINER:	Page, Thurman K
ASSISTANT EXAMINER:	Benston, Jr, William E
AGENT:	Honig, Milton L

	NUMBER	PK	DATE
PATENT INFORMATION:	US 5358714		19941025
	(CITED IN 003 LATER PATENTS)		
APPLICATION INFORMATION:	US 1992-995312		19921222
EXPIRATION DATE:	25 Oct 2011		

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
CONTINUATION OF:	US 1989-326952	19890322	ABANDONED
CONTINUATION OF:	US 1990-538601	19900614	ABANDONED
CONTINUATION OF:	US 1991-807780	19911210	ABANDONED

	NUMBER	DATE
PRIORITY APPLN. INFO.:	GB 1988-6891	19880323
FAMILY INFORMATION:	US 5358714	19941025
DOCUMENT TYPE:	UTILITY	
FILE SEGMENT:	CHEMICAL	
	GRANTED	
NUMBER OF CLAIMS:	8	

TI **COSMETIC** COMPOSITION; DIACYLGLYCEROLS AS CHEMICAL ACTIVATORS OF PROTEIN KINASE C ENZYMES FOR INDUCING AND INCREASING HAIR GROWTH

AB A preserved composition suitable for **topical** application to mammalian skin or hair for inducing, maintaining or increasing hair growth comprises: (i) a chemical activator of protein. . .

ECLM 1. A preserved composition suitable for **topical** application to mammalian skin or hair which comprises: (i) a chemical activator of protein kinass C enzymes chosen from diacylglycerols having the structure (1):

HO-CH2-CH(-O-X)-CH2-OX 1

where X is the same or different, is limited to X having a chain length containing at. . .

ACLM 8. A preserved **cosmetic** composition suitable for **topical** application to mammalian skin or hair which comprises: (i) from 0.000001 to 99.9% by weight of the composition of a. . .

=> d l12 ibib kwic 11-15

L12 ANSWER 11 OF 26 IFIPAT COPYRIGHT 2003 IFI

AN	2424425 IFIPAT;IFIUDB;IFICDB		
TITLE:	CYCLIC TERTIARY ALCOHOLS AND THEIR USE AS PERFUMING INGREDIENTS; CYCLOHEX-2-EN-1-OL STRUCTURE		
INVENTOR(S):	Decorzant, Rene , Onex, CH Naef, Ferdinand, Carouge, CH		
PATENT ASSIGNEE(S):	Firmenich SA, Geneva, CH		
PRIMARY EXAMINER:	Reamer, James H		
AGENT:	Pennie & Edmonds		

	NUMBER	PK	DATE
PATENT INFORMATION:	US 5268356		19931207
APPLICATION INFORMATION:	US 1992-969909		19921102
EXPIRATION DATE:	2 Nov 2012		

	NUMBER	DATE
PRIORITY APPLN. INFO.:	CH 1991-3444	19911125
FAMILY INFORMATION:	US 5268356	19931207
DOCUMENT TYPE:	UTILITY	
	EXPIRED	
FILE SEGMENT:	CHEMICAL	
	GRANTED	
MICROFILM REEL NO:	006307 FRAME NO: 0695	
NUMBER OF CLAIMS:	8	

ECLM 1. A compound of the formula

1-(**HO**-),1-(CH3-C(-CH3)2-),2-R2,5-R1,6-R3,6-(CH3-)CYCLO-

HEX-2-ENE I

wherein symbols R1 and R3 represent each a hydrogen atom or a methyl radical and symbol. . .

ACLM . . . cologne, a soap, a bath or shower gel, a shampoo or other

hair-care product, a body or air deodorant, a **cosmetic** preparation, a detergent or a fabric softener, or a household product.

L12 ANSWER 12 OF 26 IFIPAT COPYRIGHT 2003 IFI

AN	2373772 IFIPAT;IFIUDB;IFICDB
TITLE:	**COSMETIC** COMPOSITION AND METHODS CONTAINING DIORGANOPOLY-SILOXANES CONTAINING A 2-HYDROXYBENZOHENONE GROUP
INVENTOR(S):	Forestier, Serge, Claye-Souilly, FR Lang, Gerard, Saint-Gratien, FR Richard, Herve, Paris, FR
PATENT ASSIGNEE(S):	L'Oreal, Paris, FR
PRIMARY EXAMINER:	Ore, Dale R
AGENT:	Marshall, O'Toole, Gerstein, Murray & Borun

	NUMBER	PK	DATE
PATENT INFORMATION:	US 5223249 (CITED IN 005 LATER PATENTS)		19930629
APPLICATION INFORMATION:	US 1990-497262		19900322
EXPIRATION DATE:	29 Jun 2010		

	NUMBER	DATE
PRIORITY APPLN. INFO.:	FR 1989-3783	19890322
FAMILY INFORMATION:	US 5223249	19930629
DOCUMENT TYPE:	UTILITY EXPIRED CERTIFICATE OF CORRECTION	
CORRECTION DATE:	19 Apr 1994	
FILE SEGMENT:	CHEMICAL GRANTED	
MICROFILM REEL NO:	005324 FRAME NO: 0141	
NUMBER OF CLAIMS:	12	

TI **COSMETIC** COMPOSITION AND METHODS CONTAINING DIORGANOPOLY-SILOXANES CONTAINING A 2-HYDROXYBENZOHENONE GROUP

ECLM 1. A sunscreening **cosmetic** composition for screening UV rays with wavelengths of between 280 and 360 nm, which contains, in a cosmetically acceptable vehicle,. . . or the formula



2

in which formulas: A is a radical of formula:



(3)

X is hydrogen or linear or branched C1-C4 alkyl, p is an integer between 1 and. . .

ACLM 2. A **cosmetic** composition according to claim 1, which comprises a diorganopolysiloxane of formula (1) or (2), exhibiting at least one of the. . .

3. A **cosmetic** composition according to claim 1, which comprises a polydimethylsiloxane of formula (1) in which R and B denote methyl, r. . .

4. A **cosmetic** composition according to claim 1, which additionally contains **cosmetic** selected from the group consisting of thickeners, softeners, humectants, surfactants, preserving agents, antifoams, perfumes, oils, waxes, lanolin, lower monoalcohols, polyols,. . .

5. A **cosmetic** composition according to claim 1 which is in the form of an oily, alcoholic or oleoalcoholic lotion, an emulsion, an. . .

6. A **cosmetic** composition according to claim 5 which contains 0.25-3% by weight of diorganopolysiloxane of formula (1) or (2).
7. A **cosmetic** composition according to claim 5 which may contain other UV-B and/or UV-A screens and contains 0.5-10% by weight of diorganopolysiloxane. . .
8. A **cosmetic** composition according to claim 1 which is in the form of a composition for skin care, comprising 0.25-3% by weight. . . . . radiation with wavelengths of between 280 and 360 nm, which consists in applying thereto an effective quantity of a sunscreening **cosmetic** composition containing at least one diorganopolysiloxane having the formula:

D R A W I N G

. . .
12. A method for protecting a **cosmetic** composition against ultraviolet rays with wavelengths of between 280 and 360 nm, which consists in incorporating in said composition an. . .

L12 ANSWER 13 OF 26 IFIPAT COPYRIGHT 2003 IFI

AN	1908256 IFIPAT;IFIUDB;IFICDB
TITLE:	ANTIOXIDANT COMPRISING PROANTHOCYANIDIN AS PRINCIPAL COMPONENT; OXIDATION RESISTANCE FOR VEGETABLE OILS, FATS OR COSMETICS
INVENTOR(S):	Ariga, Toshiaki, Noda, JP Fukushima, Danji, Omiya, JP Koshiyama, Ikunori, Nagareyama, JP
PATENT ASSIGNEE(S):	Kikkoman Corporation, Noda, JP
PRIMARY EXAMINER:	Chan, Nicky
AGENT:	Banner, Birch, McKie & Beckett

	NUMBER	PK	DATE
PATENT INFORMATION:	US 4797421		19890110
	(CITED IN 014 LATER PATENTS)		
APPLICATION INFORMATION:	US 1987-102805		19870922
EXPIRATION DATE:	10 Jan 2006		

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
CONTINUATION OF:	US 1985-798620	19851115	ABANDONED
FAMILY INFORMATION:	US 4797421	19890110	
DOCUMENT TYPE:	UTILITY		
FILE SEGMENT:	CHEMICAL GRANTED		
OTHER SOURCE:	CA 111:172732		
NUMBER OF CLAIMS:	4		

ECLM . . . THE OXIDATION OF FATS AND OILS IN FOOD COMPOSITIONS AND COSMETRIC PREPARATIONS WHICH COMPRISES ADDING TO SAID FOOD COMPOSITIONS OR **COSMETIC** PREPARATIONS ABOUT 0.001 TO 2% BY WEIGHT OF A PROANTHOCYANIDIN COMPOUND WHICH EXHIBITS AN ANTIOXIDANT ACTION, SAID PROANTHOCYANIDIN COMPOUND BEING. . . BY FORMULA (4)

2-((3,4-DI(HO-)PHENYL)-),3,5,7-TRI(HO-),4-((2-((3,4-DI-(HO-)PHENYL)-),3,5,7-TRI(HO-)CHROMAN-6-YL)-)CHROMAN 4

A DIMERIC PRODELPHINIDIN REPRESENTED BY FORMULA (5)

2-((2-(3,4-DI(HO-)PHENYL)-),3,5,7-TRI(HO-)CHROMAN-8-YL)-(4,5,6-TRI(**HO**-)-**1**,2-PHENYLENE-),3,5,7-TRI(HO-)CHROMAN

A DIMERIC PROCYANIDIN B-1 GALLATE AND ITS STEREOISOMERS REPRESENTED BY FORMULA (6)

2-((3,4-DI(HO-)PHENYL)-),3-((3,4,5-TRI(HO-)PHENYL)-COO-),4-((2-((3,4-DI(HO-)PHENYL)-),3,4,5-TRI(HO-)-

. . .

ACLM 4. The method of claim 2 wherein said proanthocyanidin compound is added to said food compositions or **cosmetic** preparations as a powder, as an aqueous solution or as an alcoholic solution.

L12 ANSWER 14 OF 26 IFIPAT COPYRIGHT 2003 IFI

AN	1677296 IFIPAT;IFIUDB;IFICDB
TITLE:	STAIN-RESISTANT NYLON CARPETS IMPREGNATED WITH CONDENSATION PRODUCT OF FORMALDEHYDE WITH MIXTURE OF DIPHENOLSULFONE AND PHENOLSULFONIC ACID; IMMERSION OF NYLON CARPET IN AQUEOUS SOLUTION OF RESIN
INVENTOR(S):	Blyth, Randolph C, Gulf Breeze, FL Ucci, Pompelio A, Pensacola, FL
PATENT ASSIGNEE(S):	Monsanto Company, St Louis, MO
PRIMARY EXAMINER:	McCamish, Marion C
AGENT:	Whisler, John W

	NUMBER	PK	DATE
PATENT INFORMATION:	US 4592940		19860603
	(CITED IN 074 LATER PATENTS)		
APPLICATION INFORMATION:	US 1985-768302		19850822
EXPIRATION DATE:	16 Dec 2003		

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
CONTINUATION-IN-PART OF:	US 1983-562371	19831216	ABANDONED
FAMILY INFORMATION:	US 4592940	19860603	

DOCUMENT TYPE:	UTILITY REASSIGNED CERTIFICATE OF CORRECTION
CORRECTION DATE:	30 Dec 1986
FILE SEGMENT:	CHEMICAL GRANTED
MICROFILM REEL NO:	004448 FRAME NO: 0625
NUMBER OF CLAIMS:	10

AB Nylon carpets are rendered resistant to staining normally caused by artificial colorants such as Food, Drug and **Cosmetic** Red Dye No. 40 by immersing the carpets in a boiling aqueous solution of a selected phenol-formaldehyde condensation product at. . .

ECLM . . . OR DIFFERENT IN EACH UNIT AND IS HYDROGEN OR A RADICAL SELECTED FROM THE GROUP CONSISTING OF -SO3X,

HO-1,4-PHENYLENE-SO2- AND

HO-(2-(X-O3S-)-1,4-PHENYL-ENE)-SO2-

WITH THE PROVISO THAT AT LEAST 40% OF THE UNITS CONTAIN AN -SO3X RADICAL AND AT LEAST. . .

L12 ANSWER 15 OF 26 IFIPAT COPYRIGHT 2003 IFI

AN	1668141 IFIPAT;IFIUDB;IFICDB
TITLE:	TERTIARY HYDROXYL CARBOXALDEHYDES; ORGANOLEPTIC
INVENTOR(S):	Boden, Richard M, Ocean, NJ Fujioka, Futoshi, Wanamassa, NJ Schreiber, William L, Jackson, NJ
PATENT ASSIGNEE(S):	International Flavors & Fragrances Inc, New York, NY
PRIMARY EXAMINER:	Helfin, Bernard

AGENT: Liberman, Arthur L

	NUMBER	PK	DATE
PATENT INFORMATION:	US 4584409		19860422
APPLICATION INFORMATION:	US 1985-709808		19850308
EXPIRATION DATE:	8 Jul 2003		

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
DIVISION OF:	US 1983-551965	19830708	4491537
DIVISION OF:	US 1984-656661	19841001	
FAMILY INFORMATION:	US 4584409	19860422	
	US 4491537		

DOCUMENT TYPE: UTILITY
EXPIRED
FILE SEGMENT: CHEMICAL
GRANTED
NUMBER OF CLAIMS: 2
GRAPHICS INFORMATION: 12 Drawing Sheet(s), 14 Figure(s).
AB . . . an oxo reaction, and uses thereof in augmenting or enhancing the aroma of perfume compositions, colognes and perfumed articles (e.g., **cosmetic** powders, perfumed polymers, solid or liquid anionic, cationic, nonionic or zwitterionic detergents, fabric softener compositions, fabric softener articles, hair preparations,. . .
ECLM . . . STRUCTURE:

1-(H3C-),2-(OHC-),4-(HO-C(-CH3)2-)CYCLOHEXANE

2. A MIXTURE OF COMPOUNDS DEFINED ACCORDING TO THE STRUCTURES:

1-(H3C-),2-(OHC-),4-(HO-C(-CH3)2-)CYCLOHEXANE

1-(**HO**-),**1**-(H3C-),4-(OHC-CH2-CH(-CH3)-)CYCLOHEXANE
AND
1-(H3C-),1-(OHC-),4-(HO-C(-CH3)2-)CYCLOHEXANE

=> d l12 ibib kwic 16-26

L12 ANSWER 16 OF 26 IFIPAT COPYRIGHT 2003 IFI
AN 0902827 IFIPAT;IFIUDB;IFICDB
TITLE: HUMAN HAIR DYEING COMPOSITIONS CONTAINING DIPHENYLAMINES
INVENTOR(S): Bugaut, Andree, Boulogne-sur-Seine, FR
Estradier, Francoise, Paris, FR
Kalopissis, Gregoire, Paris, FR
PATENT ASSIGNEE(S): Societe Anonyme dite: L'Oreal, Paris, FR
PRIMARY EXAMINER: Herbert, Jr, Thomas J
ASSISTANT EXAMINER: Hess, Bruce H
AGENT: Cushman, Darby & Cushman

	NUMBER	PK	DATE
PATENT INFORMATION:	US 3853464		19741210
	(CITED IN 003 LATER PATENTS)		
APPLICATION INFORMATION:	US 1972-270633		19720711
EXPIRATION DATE:	10 Dec 1991		

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS

CONTINUATION-IN-PART OF: US 1970-61833 19700806 3792090

	NUMBER	DATE
PRIORITY APPLN. INFO.:	LU 1969-59265	19690811
FAMILY INFORMATION:	US 3853464	19741210
	US 3792090	
	DE 2039358	
	FR 2056799	
	GB 1276771	
DOCUMENT TYPE:	UTILITY	
FILE SEGMENT:	CHEMICAL	
	GRANTED	
OTHER SOURCE:	CA 74:143329	
NUMBER OF CLAIMS:	15	

ECLM . . . 2% BY WEIGHT OF A MEMBER SELECTED FROM THE GROUP CONSISTING OF (A) A DIPHENYLAMINE OF THE FORMULA

1-R1,2-Z,3-(**HO**-(**1**,4-PHENYLENE)-NH-),4-R3,5-R2,6-(R4-
N(-R5)-)-BENZENE

WHEREIN Z REPRESENTS A MEMBER SELECTED FROM THE GROUP CON-SISTING OF AMINO AND ACYLAMINO R1, R2 AND R3,. . .

ACLM 10. The composition of claim 8 which also includes a **cosmetic** resin in amounts of about 1 to 3% by weight of the total.
11. The composition of claim 10, wherein said **cosmetic** resin is selected from the group consisting of polyvinylpyrrolidone, copolymer of crotonic acid-vinyl acetate, copolymer of vinylpyrrolidone-vinyl acetate and copolymer. . .

L12 ANSWER 17 OF 26 COPYRIGHT 2003 Gale Group

ACCESSION NUMBER:	2000:123588 NLDB
TITLE:	THE MARKET REPORT.
SOURCE:	European Cosmetic Markets, (1 Apr 2000) Vol. 17, No. 4, pp. 139. ISSN: 0957-1515.
PUBLISHER:	Wilmington Publishing Ltd.
DOCUMENT TYPE:	Newsletter
LANGUAGE:	English
WORD COUNT:	9002

TX Q Are there opportunities for **cosmetic** products with additional benefits?

Christian . . . on the face with SPF8, 15 and 30; a soothing aftersun treatment and a self-tan spray. The product formulations incorporate **HSP32**, or Heat Shock Proteins, which are said to protect the skin's cells from sun damage. Lancaster (Coty/Reckitt Benckiser) has added. . .

While Hawaiian Tropic offers both sun protection and sun tanning products, Solar **Cosmetic** Labs' 2000 programme will concentrate on sun protection products to complement its No-Ad line of sun care products. No-Ad has. . .

L12 ANSWER 18 OF 26 PASCAL COPYRIGHT 2003 INIST-CNRS. ALL RIGHTS RESERVED.

ACCESSION NUMBER:	2002-0527397 PASCAL
COPYRIGHT NOTICE:	Copyright .COPYRGT. 2002 INIST-CNRS. All rights reserved.
TITLE (IN ENGLISH):	Skin antioxidants
AUTHOR:	MAIBACH Howard I.
CORPORATE SOURCE:	University of California School of Medicine, San Francisco, California, United States

SOURCE: Cosmetics and toiletries, (2002), 117(8), 28-32 [4 p.]
ISSN: 0361-4387 CODEN: CTOIDG
DOCUMENT TYPE: Journal
BIBLIOGRAPHIC LEVEL: Analytic
COUNTRY: United States
LANGUAGE: English
AVAILABILITY: INIST-6219, 354000109001330020
CT. . . Photoprotection; Prevention; Protection; Skin; Human; Toxicity; Ultraviolet radiation; Oxidative stress; Defense; Antioxidant; E-Vitamins; Ascorbic acid; Glutathione peroxidase; Catalase; Superoxide dismutase; **Heme oxygenase** (decyclizing); Glutathione; Betacarotene; Melanin; Raw materials; **Cosmetic**; Sunscreen product
CTFR. . . Protection; Peau; Homme; Toxicite; Rayonnement UV; Stress oxydatif; Defense organisme; Antioxydant; Vitamine E; Acide ascorbique; Glutathione peroxidase; Catalase; Superoxide dismutase; **Heme oxygenase** (decyclizing); Glutathion; Betacarotene; Melanine; Matiere premiere; Cosmetique; Produit antisolaire; Oxygene actif
CTES. . . Proteccion; Piel; Hombre; Toxicidad; Radiacion ultravioleta; Estres oxidativo; Defensa organismo; Antioxidante; Vitamina E; Acido ascorbico; Glutathione peroxidase; Catalase; Superoxide dismutase; **Heme oxygenase** (decyclizing); Glutation; Betacaroteno; Melanina; Materia prima; Cosmetico; Producto antisolar

L12 ANSWER 19 OF 26 SCISEARCH COPYRIGHT 2003 THOMSON ISI
ACCESSION NUMBER: 1999:851587 SCISEARCH
THE GENUINE ARTICLE: 251RK
TITLE: Biochemical studies on a novel antioxidant from lemon oil and its biotechnological, application in **cosmetic** dermatology
AUTHOR: Calabrese V (Reprint); Randazzo S D; Catalano C; Rizza V
CORPORATE SOURCE: UNIV CATANIA, DEPT CHEM, FAC MED, VLE DORIA 6, I-95125 CATANIA, ITALY (Reprint)
COUNTRY OF AUTHOR: ITALY
SOURCE: DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, (AUG 1999) Vol. 25, No. 5, pp. 219-225.
Publisher: BIOSCIENCE EDIPRINT INC, RUE ALEXANDRE-GAVARD 16, 1227 CAROUGE, SWITZERLAND.
ISSN: 0378-6501.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: English
REFERENCE COUNT: 15
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
TI Biochemical studies on a novel antioxidant from lemon oil and its biotechnological, application in **cosmetic** dermatology
STP KeyWords Plus (R): OXIDATIVE STRESS; **HEME OXYGENASE**; IRRADIATION

L12 ANSWER 20 OF 26 SCISEARCH COPYRIGHT 2003 THOMSON ISI
ACCESSION NUMBER: 1999:357384 SCISEARCH
THE GENUINE ARTICLE: 192GF
TITLE: An ex vivo biochemical model to study the antioxidant clinical properties of **cosmetic** products in human antiaging skin care
AUTHOR: Calabrese V (Reprint); Randazzo S D; Morganti P G; Rizza V
CORPORATE SOURCE: UNIV CATANIA, FAC MED, INST BIOCHEM, VLE DORIA 6, I-95125 CATANIA, ITALY (Reprint); MAVI SUD CO, APRILIA, LT, ITALY
COUNTRY OF AUTHOR: ITALY
SOURCE: DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, (DEC 1999) Vol. 25, No. 1, pp. 43-49.
Publisher: BIOSCIENCE EDIPRINT INC, RUE ALEXANDRE-GAVARD 16, 1227 CAROUGE, SWITZERLAND.
ISSN: 0378-6501.

DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: English
REFERENCE COUNT: 24
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
TI An ex vivo biochemical model to study the antioxidant clinical properties of **cosmetic** products in human antiaging skin care
STP KeyWords Plus (R): **HEME OXYGENASE**; LIPID-PEROXIDATION; OXIDATIVE STRESS; SH-GROUPS; GLUTATHIONE; FIBROBLASTS; RAT; PROTEINS; DAMAGE

L12 ANSWER 21 OF 26 SCISEARCH COPYRIGHT 2003 THOMSON ISI
ACCESSION NUMBER: 94:413995 SCISEARCH
THE GENUINE ARTICLE: NU563
TITLE: REASSESSMENT OF THE DIFFERENTIAL-EFFECTS OF ULTRAVIOLET AND IONIZING-RADIATION ON HIV PROMOTER - THE USE OF CELL-SURVIVAL AS THE BASIS FOR COMPARISONS
AUTHOR: BEER J Z (Reprint); OLVEY K M; LEE W; ZMUDZKA B Z
CORPORATE SOURCE: US FDA, CTR DEVICES & RADIOL HLTH, RADIAT BIOL BRANCH, HFZ-114, ROCKVILLE, MD, 20857 (Reprint)
COUNTRY OF AUTHOR: USA
SOURCE: PHOTOCHEMISTRY AND PHOTOBIOLOGY, (JUN 1994) Vol. 59, No. 6, pp. 643-649.
ISSN: 0031-8655.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: ENGLISH
REFERENCE COUNT: 47
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB . . . radiation treatments on the human immunodeficiency virus-1 (HIV) promoter were reassessed for exposures comparable to those encountered in clinical or **cosmetic** practice, using survival of the host cell as a basis for comparisons. The exposures were performed with two ultraviolet radiation sources commonly used as medical or **cosmetic** devices (UVASUN 2000 and FS20 lamps), a germicidal(G15T8) lamp and an X-ray machine. The UVC component of the FS20 lamp. . .
STP KeyWords Plus (R): HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; **HEME OXYGENASE** GENE; C-JUN GENE; TRANSGENIC MICE; UVA RADIATION; INVIVO ACTIVATION; DNA DAMAGE; KAPPA-B; EXPRESSION

L12 ANSWER 22 OF 26 USPATFULL
ACCESSION NUMBER: 2003:127047 USPATFULL
TITLE: Methods and compositions for regulating bone and cartilage formation
INVENTOR(S): Clancy, Brian M., Ashland, MA, UNITED STATES
Pittman, Debra D., Windham, NH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087259	A1	20030508
APPLICATION INFO.:	US 2002-125691	A1	20020418 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284786P	20010418 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02110-2600
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 12451
DETD . . . of artificial joints; repair of congenital, trauma induced, or

oncologic resection induced craniofacial defects; tooth repair processes and plastic, e.g., **cosmetic** plastic, surgery.

DETD . . . of artificial joints; repair of congenital, trauma induced, or oncologic resection induced craniofacial defects; tooth repair processes and plastic, e.g., **cosmetic** plastic, surgery.

DETD [0315] The compounds of the invention can be formulated for a variety of loads of administration, including systemic and **topical** or localized administration. Techniques and formulations generally may be found in Remmington's Pharmaceutical Sciences, Meade Publishing Co., Easton, Pa. For. . .

DETD . . . In addition, detergents may be used to facilitate permeation. Transmucosal administration may be through nasal sprays or using suppositories. For **topical** administration, the compounds of the invention can be formulated into ointments, salves, gels, or creams as generally known in the. . .

DETD . . . encapsulated or injected in a viscous form for delivery to the site of bone, cartilage, tissue damage or diseased cells. **Topical** administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than the gene-specific therapeutics which may. . .

DETD [0326] The choice of matrix material may be based on biocompatibility, biodegradability, mechanical properties, **cosmetic** appearance and interface properties. The particular application of the compositions of the invention will define the appropriate formulation. Potential matrices. . .

DETD . . .

PROCOLL-LYS., AF080572 0+/-0
2.9+/-0.4 6.2+/-2.6 15.2+/-4.4 13.5+/-1.8 11.6+/-1.7
2-OXOGLUT.5-DIOXYGEN. 2
ALK. PHOSPHATASE 2, LIVER J02980 0+/-0 0+/-0
5+/-1 6.1+/-3.6 32.6+/-2.9 18.5+/-3.8
HEME OXYGENASE (DECYCLING) 1 X13356
1.9+/-0.3 4+/-1.5 4.5+/-1.2 7.3+/-2.3 8.2+/-0.3
7.6+/-1
PROCOLL-LYS., AF046783 0+/-0
3.7+/-0.6 4.6+/-0.2 5.1+/-0.5 8.5+/-0.7 3.8+/-0.9
2-OXOGLUT. 5-DIOXYGEN. 3
PHOSPHOLIPASE A2,. . .

L12 ANSWER 23 OF 26 USPATFULL
ACCESSION NUMBER: 2002:301655 USPATFULL
TITLE: Compounds and methods for regulating cell differentiation
INVENTOR(S): Falchuk, Kenneth H., Newton, MA, UNITED STATES
PATENT ASSIGNEE(S): President & Fellows of Harvard College, Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002169201	A1	20021114
APPLICATION INFO.:	US 2001-8356	A1	20011113 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-977866, filed on 15 Oct 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240497P	20001013 (60)
	US 2000-247299P	20001110 (60)
	US 2001-262233P	20010117 (60)
	US 2001-264814P	20010129 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BANNER & WITCOFF, LTD., 28 STATE STREET, 28th FLOOR, BOSTON, MA, 02109

NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 4893
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . and/or functional performance of a wide range of cells, tissues and organs. For instance, the subject method has therapeutic and **cosmetic** applications ranging from regulation of neural tissues, bone and cartilage formation and repair, regulation of spermatogenesis, regulation of smooth muscle,. . .

DETD . . . and/or rate of survival of a cell according to clinically acceptable standards for the disorder to be treated or the **cosmetic** purpose.

DETD . . . subject method also has wide applicability to the treatment or prophylaxis of disorders afflicting epithelial tissue, as well as in **cosmetic** uses. In general, the method can be characterized as including a step of administering to an animal an amount of. . . mode of administration and dosage regimens will vary depending on the epithelial tissue(s) which is to be treated. For example, **topical** formulations will be preferred where the treated tissue is epidermal tissue, such as dermal or mucosal tissues.

DETD [0225] The subject method and compositions can also be used to treat wounds resulting from **dermatological** diseases, such as lesions resulting from autoimrnmune disorders such as psoriasis. Atopic dermititis refers to skin trauma resulting from allergies. . .

DETD . . . be used in the treatment of folliculitis, such as folliculitis decalvans, folliculitis ulerythematosa reticulata or keloid folliculitis. For example, a **cosmetic** preparation of a differeguline can be applied topically in the treatment of pseudofolliculitis, a chronic disorder occurring most often in. . .

DETD . . . carcinoma. The subject method can also be used in the treatment of autoimmune diseases affecting the skin, in particular, of **dermatological** diseases involving morbid proliferation and/or keratinization of the epidermis, as for example, caused by psoriasis or atopic dermatosis.

DETD [0237] In one embodiment, the preparations of the present invention are suitable for the treatment of **dermatological** ailments linked to keratinization disorders causing abnormal proliferation of skin cells, which disorders may be marked by either inflammatory or. . .

DETD . . . painful, however, and often produce cosmetically unacceptable scarring. Accordingly, treatment of keratosis, such as actinic keratosis, can include application, preferably **topical**, of a differeguline composition in amounts sufficient to inhibit hyperproliferation of epidermal/epidermoid cells of the lesion.

DETD . . . of lipases by Propinobacterium acnes and Staphylococcus epidermidis bacteria and Pitrosporum ovale, a yeast. Treatment with an antiproliferative differeguline, particularly **topical** preparations, may be useful for preventing the transitional features of the ducts, e.g., hypercornification, which lead to lesion formation. The. . .

DETD . . . of dermatitis caused by unwanted proliferation of epithelial cells. Such therapies for these various forms of dermatitis can also include **topical** and systemic corticosteroids, antipuritics, and antibiotics.

DETD . . . or capsule form, by injection, inhalation, eye lotion, ointment, suppository, controlled release patch, etc. administration by injection, infusion or inhalation; **topical** by lotion or ointment; and rectal by suppositories. Oral and **topical** administrations are preferred.

DETD [0249] The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and **topical** administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradernal,

intraperitoneal, transtracheal, subcutaneous, subcuticular,. . .

DETD . . . (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension; (3) **topical** application, for example, as a cream, ointment or spray applied to the skin; or (4) intravaginally or intrarectally, for example,. . .

DETD [0272] Formulations of the present invention include those suitable for oral, nasal, **topical** (including buccal and sublingual), rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and. . .

DETD [0284] Dosage forms for the **topical** or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and. . .

DETD . . . to induce differentiation of a leukemic cell. An associated biochemical phenomenon in cells exposed to TPA is the up-regulation of **heme oxygenase** 1 (**HO-1**), the enzyme that catabolizes the conversion of heme to biliverdin. As a consequence, the biliverdin content of TPA-exposed and differentiating cells is increased. The up-regulation of **HO-1** appears to be a necessary step for induction of the differentiation since inhibition of the oxygenase activity by tin protoporphyrin,. . .

DETD . . . species studied, biliverdin is formed as a product of heme breakdown in mononuclear phagocytes. In these cells, the microsomal enzyme **heme-oxygenase** catalyzes the oxidation of heme to .alpha.-OH-hemin with a ferric (Fe.sup.+3) cation (Tenhunen 1969, Ishizawa 1983). Then, in a subsequent. . .

CLM What is claimed is:

8. The method of claim 7, wherein the bilin is administered as part of a therapeutic or **cosmetic** application.

9. The method of claim 8, wherein the therapeutic or **cosmetic** application is selected from regulation of neural tissues, bone and cartilage formation and repair, regulation of spermatogenesis, regulation of smooth. . .

16. The method of claim 15, wherein the bilin is administered as part of a therapeutic or **cosmetic** application.

17. The method of claim 16, wherein the therapeutic or **cosmetic** application is selected from regulation of neural tissues, bone and cartilage formation and repair, regulation of spermatogenesis, regulation of smooth. . .

33. The method of claim 32, wherein the compound is administered as part of a therapeutic or **cosmetic** application.

34. The method of claim 33, wherein the therapeutic or **cosmetic** application is selected from regulation of neural tissues, bone and cartilage formation and repair, regulation of spermatogenesis, regulation of smooth. . .

41. The method of claim 40, wherein the compound is administered as part of a therapeutic or **cosmetic** application.

42. The method of claim 41, wherein the therapeutic or **cosmetic** application is selected from regulation of neural tissues, bone and cartilage formation and repair, regulation of spennatogenesis, regulation of smooth. . .

L12 ANSWER 24 OF 26 USPATFULL

ACCESSION NUMBER: 2002:105725 USPATFULL

TITLE: Process for the extraction of an active principle from leaves of Olea Europaea to promote the synthesis of stress proteins, obtained active principle

INVENTOR(S): Paufique, Jean-Jacques, Objat, FRANCE

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2002054927	A1	20020509
APPLICATION INFO.:	US 2001-947572	A1	20010907 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2000-11398	20000907

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: YOUNG & THOMPSON, 745 SOUTH 23RD STREET 2ND FLOOR, ARLINGTON, VA, 22202
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 248

AB The invention also covers a **cosmetic** composition and a process for improving the production of stress proteins.

SUMM . . . active principle from Olea Europaea to promote the synthesis of stress proteins, as well as the obtained active principle and **cosmetic** compositions including this active principle.

SUMM . . . molecular weight and/or their sequences, tests permitting characterization of the active principle have related to stress proteins called HSP70 and **HSP32**.

DRWD [0015] FIG. 4, a recapitulative table of the effects of temperature on the production of stress proteins **HSP 32**,

DRWD . . . a table of the effects of the active principle according to the present invention on the production of stress proteins **HSP 32** in human keratinocyte and fibroblast cultures, with and without thermal treatment, and

DRWD [0017] FIG. 6, a table of the effects-dosages of the active principle on the induction of stress proteins **HSP 32**.

DETD [0043] **HSP 32**: This enzyme is **heme-oxygenase**-1, which oxidatively cleaves heme which is a pro-oxidant molecule of carbon monoxide and biliverdine. The inductible form of this enzyme is assimilated to a stress protein and the molecular mass by electrophoresis has given its appellation **HSP 32**.

DETD [0066] **HSP 32**

DETD [0067] The same operative protocol is used but this time the quantity of RNAm of **HSP 32** is measured.

DETD [0069] In the case of **HSP 32**, it is seen that the quantity of induction is improved by thermal treatment (126% for a thermal treatment at 44.degree.. . .

DETD [0072] The invention also covers a **cosmetic** composition which includes the active principle according to the present invention and which permits increasing the production of stress proteins. . .

DETD . . . The invention also covers the process for production of stress proteins, which consists in disposing preventatively on the skin this **cosmetic** composition in an amount of at least 0.1% of active principle, preferably 1 to 5%.

CLM What is claimed is:

3. **Cosmetic** composition to increase the production of stress proteins and to guard against the effects of ultraviolet radiation, characterized in that. . .

. . . 4. Process to increase the production of stress proteins characterized in that there is preventatively disposed on the skin a **cosmetic** composition according to claim 3 in an amount of at least 0.1% of active principle.

L12 ANSWER 25 OF 26 USPATFULL
ACCESSION NUMBER: 2002:95749 USPATFULL
TITLE: Cleaning compositions comprising a specific oxygenase
INVENTOR(S): Herbots, Ivan Maurice Alfons Jan, Procter & Gamble

Eurocor N.V. 100Temselaan, B-1853 Strombeek-Bever, BELGIUM
Barnabas, Mary Vijayarani, The Procter & Gamble Company, Miami Valley Labs. 11810 E. Miami River Rd., Cincinnati, OH, United States 45061
Bettiol, Jean-Luc Philippe, Procter & Gamble Eurocor N.V. 100 Temselaan, B-1853 Strombeek-Bever, BELGIUM
Busch, Alfred, Procter & Gamble Eurocor N.V. 100 Temselaan, B-1853 Strombeek-Bever, BELGIUM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6380145	B1	20020430	
	WO 9902639		19990121	
APPLICATION INFO.:	US 2000-462559		20000110	(9)
	WO 1997-US12439		19970709	
			20000110	PCT 371 date

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Gupta, Yogendra N.
ASSISTANT EXAMINER: Elhilo, Eisa
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2894
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
SUMM . . . oxidase activity. EP 086 139 discloses the cloning and expression of the catechol 2,3 oxygenase for the food, phamaceutical and **cosmetic** industries. This enzyme is also used for the decontamination of textiles from urushiol and its derivatives and can be added. . .
SUMM . . . a polyphenol and/or heterocyclic substrate based oxygenase. Preferably said enzyme is further characterised by being an iron sulphur or iron **heme oxygenase** and/or a heavy metal dependant oxygenase.
CLM What is claimed is:
. . . claim 1 wherein said polyphenol and/or heterocyclic substrate based oxygenase is further characterized by being an iron sulphur or iron **heme oxygenase** and/or a heavy metal dependent oxygenase.

L12 ANSWER 26 OF 26 USPATFULL
ACCESSION NUMBER: 1999:106447 USPATFULL
TITLE: Method for treating heart failure using tetrapyrroles and metallotetrapyrroles
INVENTOR(S): Danziger, Robert S., New York, NY, United States
PATENT ASSIGNEE(S): The Trustees of Columbia University in the City of New York, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5948771		19990907	
APPLICATION INFO.:	US 1996-660609		19960606	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-10908P	19960131 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chang, Ceila
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1578
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
SUMM . . . and oxygen free radicals has been detected in both inflammatory and dilated cardiomyopathies (Singh, N. et al., (1995) Mol.Cell.Biochem. 147:77-81). **Heme oxygenase**, an enzyme which forms CO from heme, has been shown to be induced in myocarditis (Ewing, J. F., (1994) J.Pharm.Exp.Ther.. . .
DETD . . . hydrophilic solvents, hydrophobic solvents, polar solvents, nonpolar solvent, emollients and/or combinations thereof, optionally containing stabilizers, pH modifiers, surfactants, perfumes, astringents, **cosmetic** foundations, pigments, dyes, bioavailability modifiers and/or combinations thereof.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	131.28	296.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.65	-1.30

FILE 'STNGUIDE' ENTERED AT 19:26:29 ON 24 MAY 2003

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 23, 2003 (20030523/UP).